Aryl cyclopropyl-amino-isoquinolinyl amide compounds

ABSTRACT

Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/941,993, filed Mar. 30, 2018, which claims priority to U.S.Provisional Patent Application No. 62/643,131, filed on Mar. 14, 2018,and U.S. Provisional Patent Application No. 62/480,239, filed on Mar.31, 2017, the entire contents of each of the U.S. applications, and eachof the U.S. patents and each of the U.S. publications issued therefrom,are herein incorporated by reference.

SEQUENCE LISTING

This application contains a sequence listing having the filename1959002-00112_ST25.txt, which is 706 bytes in size, and was created onMar. 29, 2018. The entire content of this sequence listing is hereinincorporated by reference.

FIELD OF THE INVENTION

The present disclosure relates to amino isoquinolinyl amide compoundsthat affect the function of kinases and other proteins in a cell andthat are useful as therapeutic agents or with therapeutic agents. Inparticular, these compounds are useful in the treatment of eye diseasessuch as glaucoma and retinal diseases, as anti-inflammatory agents, forthe treatment of cardiovascular diseases, and for diseases characterizedby abnormal growth, such as cancers.

BACKGROUND

A variety of hormones, neurotransmitters and biologically activesubstances control, regulate or adjust the functions of living bodiesvia specific receptors located in cell membranes. Many of thesereceptors mediate the transmission of intracellular signals byactivating guanine nucleotide-binding proteins (G proteins) to which thereceptor is coupled. Such receptors are generically referred to asG-protein coupled receptors (GPCRs) and include, among others,α-adrenergic receptors, β-adrenergic receptors, opioid receptors,cannabinoid receptors and prostaglandin receptors. The biologicaleffects of activating or inhibiting these receptors is not direct, butis mediated by a host of intracellular proteins. The importance of thesesecondary proteins has been recognized and modulation of this class isnow being investigated as intervention points in disease states. One ofthe most important classes of these downstream effectors is the “kinase”class.

The various kinases play important roles in the regulation of variousphysiological functions. For example, kinases have been implicated in anumber of disease states, including, but not limited to: cardiacindications such as angina pectoris, essential hypertension,myocardial-infarction; supraventricular and ventricular arrhythmias,congestive heart failure, atherosclerosis, renal failure, diabetes,respiratory indications such as asthma, chronic bronchitis,bronchospasm, emphysema, airway obstruction, upper respiratoryindications such as rhinitis, seasonal allergies, inflammatory disease,inflammation in response to injury, rheumatoid arthritis. The importanceof p38 MAPK inhibitors in particular as new drugs for rheumatoidarthritis is reflected by the large number of compounds that has beendeveloped over the last years (J. Westra and P. C. Limburg Mini-Reviewsin Medicinal Chemistry Volume 6, Number 8, Aug. 2006). Other conditionsinclude chronic inflammatory bowel disease, glaucoma, hypergastrinemia,gastrointestinal indications such as acid/peptic disorder, erosiveesophagitis, gastrointestinal hypersecretion, mastocytosis,gastrointestinal reflux, peptic ulcer, Zollinger-Ellison syndrome, pain,obesity, bulimia nervosa, depression, obsessive-compulsive disorder,organ malformations (e.g., cardiac malformations), neurodegenerativediseases such as Parkinson's Disease and Alzheimer's Disease, multiplesclerosis, Epstein-Barr infection and cancer (Nature Reviews DrugDiscovery 2002, 1: 493-502). In other disease states, the role ofkinases is only now becoming clear. The retina is a complex tissuecomposed of multiple interconnected cell layers, highly specialized fortransforming light and color into electrical signals that are perceivedby the brain. Damage or death of the primary light-sensing cells, thephotoreceptors, results in devastating effects on vision. Despite theidentification of numerous mutations that cause inherited retinaldegenerations, the cellular and molecular mechanisms leading from theprimary mutations to photoreceptor apoptosis are not well understood,but may involve the wnt pathway (AS Hackam “The Wnt Signaling Pathway inRetinal Degeneration” IUBMB Life Volume 57, Number 6/Jun. 2005).

The success of the tyrosine-kinase inhibitor STI571 (Gleevec) in thetreatment of chronic myelogenous leukemia (Nature Reviews Drug Discovery2003, 2: 296-313) has spurred considerable efforts to develop otherkinase inhibitors for the treatment of a wide range of other cancers(Nature Reviews Cancer 2003, 3: 650-665). The balance between theinitiation and the inactivation of intracellular signals determines theintensity and duration of the response of the receptors to stimuli suchas agonists. When desensitization occurs, the mediation or regulation ofthe physiological function mediated or regulated by the G proteins towhich the receptors are coupled is reduced or prevented. For example,when agonists are administered to treat a disease or condition byactivation of certain receptors, the receptors relatively quickly becomedesensitized from the action of the GRKs such that agonistadministration may no longer result in therapeutic activation of theappropriate receptors. At that point, administration of the agonist nolonger enables sufficient or effective control of or influence on thedisease or condition intended to be treated.

Janus Kinases (or JAK) are a family of cytoplasmic protein tyrosinekinases. The JAK family plays a role in the cytokine-dependentregulation of proliferation and function of cells involved in immuneresponse. Currently, there are four JAK family members are known JAK1,JAK2, JAK3, and TYK2. The JAKs usually associate with cytokine receptorsin pairs as homodimers or heterodimers. Specific cytokines areassociated with specific JAK pairings. Each of the four members of theJAK family is implicated in the signaling of at least one of thecytokines associated with inflammation. Binding of cytokine to aJAK-dependent cytokine receptor induces receptor dimerization whichresults in phosphorylation of tyrosine residues on the JAK kinase,effecting JAK activation. Phosphorylated JAKs, in turn, bind andphosphorylate various STAT proteins which dimerize, internalize in thecell nucleus and directly modulate gene transcription, leading, amongother effects, to the downstream effects associated with inflammatorydisease.

In view of the role that kinases play in many disease states, there isan urgent and continuing need for small molecule ligands which inhibitor modulate the activity of kinases. Without wishing to be bound bytheory, it is thought that modulation of the activity of kinases, inparticular ROCK and JAK kinases, by the compounds of the presentdisclosure is, at least in part, responsible for their beneficialeffects.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows changes (reductions) in rabbit IOP achieved viaintracameral injection of a formulation of a(1R,2R)—N-(fluoroisoquinolin-6-yl)-2-(4-(pyridinylmethyl) phenyl)cyclopropane-1-carboxamide.

SUMMARY

In an aspect, the present disclosure provides a compound according toFormula (I):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ia):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —NR^(N1)(CR¹ ₂)_(m)—, —S(O)₂—,—C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—, or C₁₋₆ alkylene;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ib):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(m)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or Cis alkylene;

R is halogen, cyano, OR³, amino, cycloalkyl, heterocyclyl, aryl, orheteroaryl, or R may form a ring of 5 to 7 member atoms with R^(N1) orR¹, wherein the ring may contain up to 2 heteroatoms selected from N, O,and S, the ring being either saturated or unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or Cis alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ic):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperedine, or forms a ring with R;

R¹ is F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Id):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is 2, 3, 4, 5, or 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound is a compoundof Formula (II):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,C₁₋₆ alkylene alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound is a compoundof Formula (III):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (IV):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,C₁₋₆ alkylene, alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (VII):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocycylaryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R; R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (VIII):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl, heterocycyl,aryl, or heteroaryl, or R may form a ring of 5 to 7 member atoms withR^(N1) or R¹, wherein the ring may contain up to 2 heteroatoms selectedfrom N, O, and S, the ring being either saturated or unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (IX):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In one aspect, provided herein are compounds of Formula (X):

or a pharmaceutically acceptable salt thereof,

wherein,

R¹ is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl;

R² is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl;

or R¹ and R², together with the nitrogen to which they are attached,form a heterocyclyl;

R³ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

R⁴ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

X is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl;

Y is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl; and

Z is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl.

In an aspect, the present disclosure provides a pharmaceuticalcomposition comprising a compound according to the present disclosureand a pharmaceutically acceptable excipient.

In an aspect, the present disclosure provides a method of treating anocular disorder in a subject in need of treatment, comprisingadministering to the subject a compound or composition according to thepresent disclosure.

In an aspect, the present disclosure provides a method of reducingintraocular pressure in a subject in need thereof, comprisingadministering to an eye of the subject a compound or compositionaccording to the present disclosure.

In an aspect, the present disclosure provides a kit comprising acompound or composition of according to the present disclosure andinstructions for use.

DETAILED DESCRIPTION

Publications and patents are referred to throughout this disclosure. AllU.S. patents cited herein are hereby incorporated by reference. Allpercentages, ratios, and proportions used herein are percent by weightunless otherwise specified.

Arylcyclopropyl amino-isoquinolinyl amides are provided.

“Alkyl” refers to a saturated aliphatic hydrocarbon including straightchain and branched chain groups. “Alkyl” may be exemplified by groupssuch as methyl, ethyl, n-propyl, isopropyl, n-butyl and the like. Alkylgroups may be substituted or unsubstituted. More than one substituentmay be present. Substituents may also be themselves substituted. Whensubstituted, the substituent group is preferably but not limited toC₁-C₄ alkyl, aryl, heteroaryl, amino, thioalkyl, cyano, halogen, alkoxyor hydroxyl. “C₁-C₄ alkyl” refers to alkyl groups containing one to fourcarbon atoms.

“Alkenyl” refers to an unsaturated aliphatic hydrocarbon moietyincluding straight chain and branched chain groups. Alkenyl moietiesmust contain at least one alkene. “Alkenyl” may be exemplified by groupssuch as ethenyl, n-propenyl, isopropenyl, n-butenyl and the like.Alkenyl groups may be substituted or unsubstituted. More than onesubstituent may be present. When substituted, the substituent group ispreferably alkyl, halogen or alkoxy. Substituents may also be themselvessubstituted. Substituents can be placed on the alkene itself and also onthe adjacent member atoms or the alkynyl moiety. “C₂-C₄ alkenyl” refersto alkenyl groups containing two to four carbon atoms.

“Alkynyl” refers to an unsaturated aliphatic hydrocarbon moietyincluding straight chain and branched chain groups. Alkynyl moietiesmust contain at least one alkyne. “Alkynyl” may be exemplified by groupssuch as ethynyl, propynyl, n-butynyl and the like. Alkynyl groups may besubstituted or unsubstituted. More than one substituent may be present.Substituents are not on the alkyne itself but on the adjacent memberatoms of the alkynyl moiety. When substituted, the substituent group ispreferably alkyl, amino, cyano, halogen, alkoxyl or hydroxyl.Substituents may also be themselves substituted. “C₂-C₄ alkynyl” refersto alkynyl groups containing two to four carbon atoms.

“Acyl” or “carbonyl” refers to the group —C(O)R wherein R is hydrogen,alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclic,heterocarbocyclic, C₁-C₄ alkyl aryl or C₁-C₄ alkyl heteroaryl. C₁-C₄alkylcarbonyl refers to a group wherein the carbonyl moiety is precededby an alkyl chain of 1-4 carbon atoms.

“Alkoxy” refers to the group —O—R wherein R is alkyl, alkenyl, acyl,alkyl alkenyl, alkyl alkynyl, aryl, carbocyclic, heterocarbocyclic,heteroaryl, C₁-C₄ alkyl aryl or C₁-C₄ alkyl heteroaryl.

“Amino” refers to the group —NR′R′ wherein each R′ is, independently,hydrogen, amino, hydroxyl, alkoxyl, alkyl, aryl, cycloalkyl,heterocycloalkyl, heteroaryl, C₁-C₄ alkyl aryl or C₁-C₄ alkylheteroaryl. The two R′ groups may themselves be linked to form a ring.The R′ groups may themselves be further substituted, in which case thegroup also known as guanidinyl is specifically contemplated under theterm ‘amino”.

“Aryl” refers to an aromatic carbocyclic group. “Aryl” may beexemplified by phenyl. The aryl group may be substituted orunsubstituted. More than one substituent may be present. Substituentsmay also be themselves substituted. When substituted, the substituentgroup is preferably but not limited to alkyl, alkenyl, heteroaryl, acyl,carboxyl, sulfonyl, sulfonylamino, thioalkyl, trifluoromethyl,carbonylamino, amino, cyano, halogen, or hydroxyl.

“Carboxyl” refers to the group —C(═O)O—C₁-C₄ alkyl.

“Carbonyl” refers to the group —C(O)R wherein each R is, independently,hydrogen, alkyl, aryl, cycloalkyl; heterocycloalkyl; heteroaryl, C₁-C₄alkyl aryl or C₁-C₄ alkyl heteroaryl. “Carbonylamino” refers to thegroup —C(O)NR′R′ wherein each R′ is, independently, hydrogen, alkyl,aryl, cycloalkyl; heterocycloalkyl; heteroaryl, C₁-C₄ alkyl aryl orC₁-C₄ alkyl heteroaryl. The two R′ groups may themselves be linked toform a ring.

“C₁-C₄ alkyl aryl” refers to C₁-C₄ alkyl groups having an arylsubstituent such that the aryl substituent is bonded through an alkylgroup. “C₁-C₄ alkyl aryl” may be exemplified by benzyl. “C₁-C₄ alkylheteroaryl” refers to C₁-C₄ alkyl groups having a heteroaryl substituentsuch that the heteroaryl substituent is bonded through an alkyl group.

“Carbocyclic group” or “cycloalkyl” means a saturated or unsaturatedhydrocarbon ring. Carbocyclic groups are monocyclic, or are fused,spiro, or bridged bicyclic ring systems. Monocyclic carbocyclic groupscontain 3 to 10 carbon atoms, preferably 4 to 7 carbon atoms, and morepreferably 5 to 6 carbon atoms in the ring. Bicyclic carbocyclic groupscontain 8 to 12 carbon atoms, preferably 9 to 10 carbon atoms in thering. Carbocyclic groups may be substituted or unsubstituted. More thanone substituent may be present. Substituents may also be themselvessubstituted. Suitable substituents include halogen, cyano, alkoxyl,amino, trifluoromethyl, and trifluoromethoxyl. Preferred carbocyclicgroups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cyclohexenyl, and cycloheptyl. The most preferred carbocyclic groups arecyclohexyl and cyclopentyl. Carbocyclic groups are not aromatic.

“Halogen” refers to fluoro, chloro, bromo or iodo moieties. Preferably,the halogen is fluoro, chloro, or bromo.

“Heteroaryl” or “heteroaromatic” refers to a monocyclic or bicyclicaromatic carbocyclic radical having one or more heteroatoms in thecarbocyclic ring. Heteroaryl may be substituted or unsubstituted. Morethan one substituent may be present. When substituted, the substituentsmay themselves be substituted. Preferred but non limiting substituentsare halogen, cyano, alkoxyl, amino, trifluoromethyl, trifluoromethoxyl,aryl, C₁-C₄ alkylaryl, hydroxyl, carboxyl, carbonylamino, or C₁-C₄alkyl. Preferred heteroaromatic groups include benzo[b]thiophenyl,pyrrolidyl, benzofuranyl, isoquinolinyl, imidazolyl, quinolinyl,cinnolinyl, tetrazoyl, triazolyl, thienyl, thiazolyl, purinyl,pyrimidyl, pyridyl, and furanyl. More preferred heteroaromatic groupsinclude isoquinolinyl, benzo[b]thiophenyl; thienyl, furanyl, tetrazoyl,triazolyl, and pyridyl.

“Heteroatom” means a polyvalent atom other than carbon in the ring of aheterocyclic group or a heteroaromatic group or the chain of aheterogeneous group. Preferably, heteroatoms are selected from the groupconsisting of nitrogen, sulfur, and oxygen atoms. Groups containing morethan one heteroatom may contain different heteroatoms. Halogens aremonovalent and thus are not considered heteroatoms in this sense, buthave their own category.

“Heterocarbocyclic group” or “heterocycloalkyl” or “heterocyclic” meansa saturated or unsaturated hydrocarbon ring containing at least oneheteroatom. Heterocarbocyclic groups are monocyclic, or are fused,spiro, or bridged bicyclic ring systems. Monocyclic heterocarbocyclicgroups contain 3 to 10 carbon atoms, preferably 4 to 7 carbon atoms, andmore preferably 5 to 6 carbon atoms in the ring. Bicyclicheterocarbocyclic groups contain 8 to 12 carbon atoms, preferably 9 to10 carbon atoms in the ring. Heterocarbocyclic groups may be substitutedor unsubstituted. More than one substituent may be present. Substituentsmay also be themselves substituted. Suitable substituents includehalogen, nitrile, hydroxyl, alkoxyl, amino, trifluoromethyl, andtrifluoromethoxyl. Preferred heterocarbocyclic groups include epoxy,tetrahydrofuranyl, azacyclopentyl, (or pyrrolidyl), azacyclohexyl,piperidyl, and homopiperidyl More preferred heterocarbocyclic groupsinclude pyrrolidyl, piperidyl, and homopiperidyl. The most preferredheterocarbocyclic group is piperidyl. Heterocarbocyclic groups are notaromatic.

“Hydroxy” or “hydroxyl” means a chemical entity that consists of —OH.Alcohols contain hydroxy groups. Hydroxy groups may be free orprotected. An alternative name for hydroxy is hydroxyl.

“Linker” means a linear chain of n member atoms where n is an integerfrom 1 to 4.

“Member atom” means a carbon, nitrogen, oxygen or sulfur atom. Memberatoms may be substituted up to their normal valence. If more than onestable valence is available for a member atom, e.g., sulfur, then allstable valences are contemplated. If substitution is not completelyspecified, the unspecified substituents required for valency arehydrogen.

“Ring” means a collection of member atoms that are cyclic. Rings may becarbocyclic, aromatic, or heterocyclic or heteroaromatic, and may besubstituted or unsubstituted, and may be saturated or unsaturated. Morethan one substituent may be present. Ring junctions with the main chainmay be fused or spirocyclic. Rings may be monocyclic or bicyclic. Ringscontain at least 3 member atoms and at most 10 member atoms. Monocyclicrings may contain 3 to 7 member atoms and bicyclic rings may containfrom 8 to 12 member atoms. Bicyclic rings themselves may be fused orspirocyclic.

“Thioalkyl” refers to the group —S— alkyl.

“Sulfonyl” refers to the —S(O)₂R′ group wherein R′ is alkoxy, alkyl,aryl, carbocyclic, heterocarbocyclic; heteroaryl, C₁-C₄ alkyl aryl orC₁-C₄ alkyl heteroaryl.

“Sulfonylamino” refers to the —S(O)₂NR′R′ group wherein each R′ isindependently alkyl, aryl, heteroaryl, C₁-C₄ alkyl aryl or C₁-C₄ alkylheteroaryl.

“Pharmaceutically acceptable carrier” means a carrier that is useful forthe preparation of a pharmaceutical composition that is: generallycompatible with the other ingredients of the composition, notdeleterious to the recipient, and neither biologically nor otherwiseundesirable. “A pharmaceutically acceptable carrier” includes both oneand more than one carrier. Embodiments include carriers for topical,ocular, parenteral, intravenous, intraperitoneal intramuscular,sublingual, nasal and oral administration. “Pharmaceutically acceptablecarrier” also includes agents for preparation of aqueous dispersions andsterile powders for injection or dispersions.

“Excipient” as used herein includes physiologically compatible additivesuseful in preparation of a pharmaceutical composition. Examples ofpharmaceutically acceptable carriers and excipients can for example befound in Remington Pharmaceutical Science, 16^(th) Ed.

“Therapeutically effective amount” as used herein refers to a dosage ofthe compounds or compositions effective for influencing, reducing orinhibiting the activity of or preventing activation of a kinase. Thisterm as used herein may also refer to an amount effective at bringingabout a desired in vivo effect in an animal, preferably, a human, suchas reduction in intraocular pressure.

“Administering” as used herein refers to administration of the compoundsas needed to achieve the desired effect.

“Eye disease” as used herein includes, but is not limited to, glaucoma,allergy, cancers of the eye, neurodegenerative diseases of the eye, suchas diabetic eye disease, macular degeneration (AMD), inflammation, anddry eye.

The term “disease or condition associated with kinase activity” is usedto mean a disease or condition treatable, in whole or in part, byinhibition of one or more kinases.

The term “controlling the disease or condition” is used to mean changingthe activity of one or more kinases to affect the disease or condition.

The term “contacting a cell” is used to mean contacting a cell in vitroor in vivo i.e. in a subject, such as a mammal, including humans,rabbits, cats and dogs.

Compounds

In an aspect, the compound according to Formula (I) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(m)—, —C(O)O—, —OC(O)—,—S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆ alkylene, aryl, or heteroaryl;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, acyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ia):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —NR^(N1)(CR¹ ₂)_(m)—, —S(O)₂—,—C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—, or C₁₋₆ alkylene;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ib):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is halogen, cyano, OR³, amino, cycloalkyl, heterocyclyl, aryl, orheteroaryl, or R may form a ring of 5 to 7 member atoms with R^(N1) orR¹, wherein the ring may contain up to 2 heteroatoms selected from N, O,and S, the ring being either saturated or unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Ic):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₃alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(nr), —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperedine, or forms a ring with R;

R¹ is F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the present disclosure provides a compound according toFormula (Id):

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹ ₂)_(n)—,—(R)O—C₁₋₆ alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, carbonyl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl, NH₂, SO₂-aryl, SO₂-heteroaryl, morpholine orpiperidine, or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is 2, 3, 4, 5, or 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (II) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof, wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (III) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl,

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (IV) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R; R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (V) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (VI) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(m)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (VII) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (VIII) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, —C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆ alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In an aspect, the compound according to Formula (IX) is provided:

or tautomers, stereoisomers and pharmaceutically acceptable saltsthereof,wherein:

X₁, X₂ and X₃ are independently H, halogen, nitrile, hydroxyl, or C₁₋₆alkyl;

Y is —NR^(N1)S(O)₂—, —NR^(N1)C(O)—, —O(CR¹ ₂)_(n)—, —NR^(N1)(CR¹₂)_(m)—, C(O)O—, —OC(O)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O—, C₁₋₆alkylene, aryl, or heteroaryl;

Z is a direct bond or C₁₋₆ alkylene;

R is H, halogen, cyano, OR³, C₁₋₆ alkyl, amino, cycloalkyl,heterocyclyl, aryl, or heteroaryl, or R may form ring, of 5 to 7 memberatoms with R^(N1) or R¹, wherein the ring, may contain up to 2heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated;

R^(N1) is H or C₁₋₆alkyl or forms a ring with R;

R¹ is H, F, or Me or forms a ring with R;

R³ is H or C₁₋₆ alkyl;

n is an integer from 0 to 6; and

m is an integer from 1 to 6.

In embodiments for Formulas (I)-(IX), one or more of X¹, X², and X³ arehydrogen. In embodiments for Formulas (I)-(IX), X¹ is OH, CN, F, Br, Clor CH₃. In embodiments for Formulas (I)-(IX), X² is CN, F, Br, Cl orCH₃. In embodiments for Formulas (I)-(IX), X³ is —CF₃, —OCH₃, CN, F, Br,Cl, OCF₃ or CH₃.

In embodiments for Formulas (I)-(IX), R^(N1) is H. Alternatively, R^(N1)is C₁₋₆ alkyl, which may be substituted.

In embodiments for Formulas (I)-(IX), R is amino. Alternatively, R isheteroaryl, heterocyclyl, or aryl, such as phenyl, pyridyl, piperidinyl,morpholino, thiophenyl, isoquinolinyl, quinolinyl or pyrrolidinyl. Inembodiments for Formulas (I)-(IX), R is H, C₁₋₆ alkyl, cycloalkyl, orheterocyclyl, or R may form a ring of 5 to 7 member atoms with R^(N1),wherein the ring may contain up to 2 heteroatoms selected from N, O, andS, which may be saturated or unsaturated.

In embodiment for Formulas (I)-(IX), Z is a direct bond. Alternatively,Z is C₁₋₆ alkylene, such as —CH₂—.

In embodiments for Formulas (I)-(IX), Y is —NR^(N1)S(O)₂—. Inembodiments for Formulas (I)-(IX), Y is —NR^(N1)S(O)₂— and R^(N1) is H.In embodiments, Y is —NR^(N1)S(O)₂— and R is alkyl, aryl, heteroaryl,carbocyclyl, or heterocyclyl.

In embodiments for Formulas (I)-(IX), Y is —NR^(N1)C(O)—. In embodimentsfor Formulas (I)-(IX), Y is —NR^(N1)C(O)— and R is piperidinyl,morpholino, thiophenyl, isoquinolinyl, quinolinyl, thiofuranyl,benzothiophenyl, or pyrrolidinyl. In embodiments for Formulas (I)-(IX),Y is —NR^(N1)C(O)— and R is H, C₁₋₆ alkyl, cycloalkyl, or heterocyclyl,or R may form a ring of 5 to 7 member atoms with R^(N1), wherein thering may contain up to 2 heteroatoms selected from N, O, and S, whichmay be saturated or unsaturated. In embodiments, Y is —NR^(N1)C(O)—, Ris piperidinyl, R^(N1) is H, Z is —CH₂— and X¹, X², and X³ are H. Inembodiments, Y is —NR^(N1)C(O)—R is isoquinolinyl, R^(N1) is H, Z is adirect bond, and X¹, X², and X³ are H.

In embodiments for Formulas (I)-(IX), Y is —O(CR¹ ₂)_(n)—. Inembodiments, Y is —O(CR¹ ₂)_(n)— and R is cycloalkyl, heterocyclyl, orheteroaryl, or R may form a ring of 5 to 7 member atoms with R¹, whereinthe ring may contain up to 2 heteroatoms selected from N, O, and S,which may be saturated or unsaturated.

In embodiments for Formulas (I)-(IX), Y is —NR^(N1)(CR¹ ₂)_(m)—. Inembodiments for Formulas (I)-(IX), Y is —NR^(N1)(CR¹ ₂)_(m)— and R is H,C₁₋₆ alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, or R may forma ring of 5 to 7 member atoms with R^(N1), wherein the ring may containup to 2 heteroatoms selected from N, O, and S, which may be saturated orunsaturated.

In embodiments for Formulas (I)-(IX), Y is —C(O)O— or —OC(O)—. Inembodiments for Formulas (I)-(IX), Y is —C(O)O— or —OC(O)— and R is H,cycloalkyl, heterocyclyl, aryl, or heteroaryl and wherein Z is a directbond.

In some embodiments of these aspects, Y is —NR^(N1)S(O)₂—,—NR^(N1)C(O)—, —NR^(N1)(CR¹ ₂)_(m)—, —S(O)₂—, —C(O)—, —NR^(N1)C(O)O(CR¹₂)_(n)—, or C₁₋₆ alkylene.

In some embodiments of these aspects, R is halogen, cyano, OR³, amino,cycloalkyl, heterocyclyl, aryl, or heteroaryl, or R may form a ring of 5to 7 member atoms with R^(N1) or R¹, wherein the ring may contain up to2 heteroatoms selected from N, O, and S, the ring being either saturatedor unsaturated.

In some embodiments of these aspects, R¹ is F, or Me or forms a ringwith R.

In some embodiments of these aspects, n is 2, 3, 4, 5, or 6.

Compounds according to the present disclosure include those shown inTable 1.

TABLE 1

Compounds according to the disclosure also include:

In another aspect, provided herein are compounds of Formula (Xa):

or a pharmaceutically acceptable salt thereof,

wherein,

R¹ is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, alkyl)-heterocyclyl orheterocycloalkyl;

R² is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl;

or R¹ and R², together with the nitrogen to which they are attached,form a -heterocycle or a heterocycle substituted with —C₁₋₆ alkyl;

R³ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

R⁴ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

X is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl;

Y is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl; and

Z is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl.

In an embodiment, the compound of Formula (Xa) is a compound of Formula(X):

or a pharmaceutically acceptable salt thereof,

wherein,

R¹ is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl;

R² is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl;

or R¹ and R², together with the nitrogen to which they are attached,form a -heterocycle;

R³ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

R⁴ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl;

X is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl;

Y is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl; and

Z is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl, halogen or hydroxyl.

In an embodiment, the compound of Formula (X) is a compound of Formula(XI):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XII):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XIII):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XIV):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XV):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XVI):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XVII):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XVIII):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XIV):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XX):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XXI):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XXII):

or a pharmaceutically acceptable salt thereof.

In an embodiment, the compound of Formula (X) is a compound of Formula(XXIII):

or a pharmaceutically acceptable salt thereof.

In some embodiments of the Formulae provided herein, the compound istrans (±) with respect to the stereocenters of the cyclopropyl ring ofthe compound. In some embodiments of the Formulae provided herein, thecompound is (R,R) with respect to the stereocenters of the cyclopropylring of the compound. In some embodiments of the Formulae providedherein, the compound is (S,S) with respect to the stereocenters of thecyclopropyl ring of the compound.

In some embodiments of the Formulae provided herein,

R¹ is H, —C₁₋₆ alkyl, aryl, heteroaryl, —(C₁₋₆ alkyl)-pyridinyl,alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl;

R² is H, —C₁₋₆ alkyl, aryl, heteroaryl, —(C₁₋₆ alkyl)-pyridinyl, —(C₁₋₆alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl;

or R¹ and R², together with the nitrogen to which they are attached,form a heterocycle;

R³ is H or C₁₋₆ alkyl;

R⁴ is H or C₁₋₆ alkyl;

X is H, C₁₋₆ alkyl, halogen or hydroxyl;

Y is H, C₁₋₆ alkyl, halogen or hydroxyl; and

Z is H, C₁₋₆ alkyl, halogen or hydroxyl.

In some embodiments of the Formulae provided herein,

R¹ is H, —C₁₋₄ alkyl, aryl, heteroaryl, —(C₁₋₄ alkyl)-pyridinyl, —(C₁₋₄alkyl)-N(R³)R⁴, —(C₁₋₄ alkyl)-heterocyclyl or heterocycloalkyl;

R² is H, —C₁₋₄ alkyl, aryl, heteroaryl, —(C₁₋₄ alkyl)-pyridinyl, —(C₁₋₄alkyl)-N(R³)R⁴, —(C₁₋₄ alkyl)-heterocyclyl or heterocycloalkyl;

or R¹ and R², together with the nitrogen to which they are attached,form a heterocycle; R³ is H or C₁₋₄ alkyl;

R⁴ is H or C₁₋₄ alkyl;

X is H, C₁₋₄ alkyl, halogen or hydroxyl;

Y is H, C₁₋₄ alkyl, halogen or hydroxyl; and

Z is H, C₁₋₄ alkyl, halogen or hydroxyl.

In some embodiments of the Formulae provided herein,

R¹ is H, phenyl, pyridinyl, —(C₁₋₆ alkyl)-pyridinyl, —(C₁₋₆alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl; and

R² is H, phenyl, pyridinyl, —(C₁₋₆ alkyl)-pyridinyl, —(C₁₋₆alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl.

In some embodiments of the Formulae provided herein,

R¹ is H; and

R² is H, phenyl, pyridinyl, —(C₁₋₆ alkyl)-pyridinyl, alkyl)-N(R³)R⁴,—(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl.

In some embodiments of the Formulae provided herein, R¹ is H or —C₁₋₆alkyl.

In some embodiments of the Formulae provided herein, R¹ is —C₁₋₆ alkyl.

In some embodiments of the Formulae provided herein, R¹ is H.

In some embodiments of the Formulae provided herein, R² is phenyl,pyridinyl, —(C₁ alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆alkyl)-heterocyclyl or heterocycloalkyl.

In some embodiments of the Formulae provided herein, pyridinyl is2-pyridinyl.

In some embodiments of the Formulae provided herein, pyridinyl is3-pyridinyl.

In some embodiments of the Formulae provided herein, pyridinyl is4-pyridinyl.

In some embodiments of the Formulae provided herein, R² is phenyl,pyridinyl, —(C₁₋₆ alkyl)-pyridinyl, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl.

In some embodiments of the Formulae provided herein, R² is —(C₁₋₆alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl;

In some embodiments of the Formulae provided herein, R² is phenyl,pyridinyl, —(C₁₋₆ alkyl)-pyridinyl.

In some embodiments of the Formulae provided herein, R² is pyridinyl.

In some embodiments of the Formulae provided herein, R¹ and R², togetherwith the nitrogen to which they are attached, form a heterocyclylcontaining six ring atoms.

In some embodiments of the Formulae provided herein, R¹ and R², togetherwith the nitrogen to which they are attached, form a heterocyclylcontaining six ring atoms, wherein one or two of the ring atoms are,independently, O, S or N.

In some embodiments of the Formulae provided herein, R¹ and R², togetherwith the nitrogen to which they are attached, form a heterocyclylcontaining six ring atoms, wherein one or two of the ring atoms are N.

In some embodiments of the Formulae provided herein, R³ and R⁴ are H.

In some embodiments of the Formulae provided herein, R³ and R⁴ are,independently, C₁₋₆ alkyl.

In some embodiments of the Formulae provided herein, R³ is H, and R⁴ isC₁₋₆ alkyl.

In some embodiments of the Formulae provided herein, X, Y and Z are H.

In some embodiments of the Formulae provided herein,

X is C₁₋₆ alkyl, halogen or hydroxyl; and

Y and Z are H.

In some embodiments of the Formulae provided herein,

X is halogen; and

Y and Z are H.

In some embodiments of the Formulae provided herein, X is C₁₋₆ alkyl,halogen or hydroxyl.

In some embodiments of the Formulae provided herein, X is methyl, ethyl,CF₃, CHF₂ or CH₂F.

In some embodiments of the Formulae provided herein, Y is methyl, ethyl,CF₃, CHF₂ or CH₂F.

In some embodiments of the Formulae provided herein, Z is methyl, ethyl,CF₃, CHF₂ or CH₂F.

In some embodiments of the Formulae provided herein, X is halogen.

In some embodiments of the Formulae provided herein, X is F or Cl.

In some embodiments of the Formulae provided herein, X is Cl.

In some embodiments of the Formulae provided herein,

X is methyl or halogen;

Y is methyl or halogen; and

Z is methyl or halogen.

In some embodiments of the Formulae provided herein,

X is methyl, F or Cl;

Y is methyl, F or Cl; and

Z is methyl, F or Cl.

In some embodiments of the Formulae provided herein,

X is halogen; and Y is hydroxyl.

In some embodiments of the Formulae provided herein, Y is hydroxyl.

In some embodiments of the Formulae provided herein, Z is H or F.

In some aspects, provided herein is a compound of Formula (1):

or a pharmaceutically acceptable salt thereof;

wherein

Y is —C₁₋₆-alkyl, —O—, —(CH₂)₁₋₂O C(O)N(H)—, —(CH₂)₁₋₂N(H)—, —C(O)N(H)—(i.e. an amide) or —C(O)O— (i.e. an ester);

X¹ is H, —OH, —C₁₋₃-alkyl (e.g., methyl), or halogen (e.g., F, Br orCl);

X² is H or halogen (e.g., F, Cl or Br);

X³ is H or halogen (e.g., F, Cl or Br);

Z is a bond, —S(O)₂—, ethenyl, ethynyl, methylene, ethylene, orpropylene, or Z, together with the nitrogen to which Z is attached formsa —C₂₋₆-heterocyloalkyl; and

R is —OH, —NH₂, —NH(C₁₋₃-alkyl), —N(C₁₋₃-alkyl)(C₁₋₃-alkyl),—C(O)O—(C₁₋₆-alkyl), —N(H)C(O)—(C₁₋₆-alkyl), —C₁₋₃-alkyl, pyridinyl,phenyl, halophenyl, methoxyphenyl, monohalomethoxyphenyl,diihalomethoxyphenyl, trihalomethoxyphenyl, monohalomethyl,dihalomethyl, trihalomethyl, thienyl, halothienyl, thiazolyl,benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl, oxydiaryl (e.g.,oxydiphenyl, oxydinaphthalenyl, or phenoxynaphthalenyl), or R is—C₂₋₆-heterocyloalkyl unsubstituted or substituted with one or more of—C₁₋₆-alkyl, halo, benzyl, halobenzyl, pyridinyl, carbonyl,monohalomethyl, dihalomethyl, trihalomethyl, or —C(O)O—(C₁₋₆-alkyl);

or Y and Z together are a bond, and R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(C₁₋₃-alkyl)(C₁₋₃-alkyl), —N(H)C(O)—(C₁₋₆-alkyl), —C(O)NH₂,—C₁₋₃-alkyl, pyridinyl, phenyl, halophenyl, methoxyphenyl,monohalomethoxyphenyl, diihalomethoxyphenyl, trihalomethoxyphenyl,monohalomethyl, dihalomethyl, trihalomethyl, thienyl, halothienyl,thiazolyl, benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl,oxydiaryl (e.g., oxydiphenyl, oxydinaphthalenyl, orphenoxynaphthalenyl), or R is —C₂₋₆-heterocyloalkyl unsubstituted orsubstituted with one or more of —C₁₋₆-alkyl, halo, benzyl, halobenzyl,pyridinyl, carbonyl, monohalomethyl, dihalomethyl, trihalomethyl, or—C(O)O—(C₁₋₆-alkyl).

In some embodiments, Y is —C(O)N(H)— (i.e. an amide). In someembodiments, Y is —C(O)O— (i.e. an ester). In some embodiments, Y is—C₁₋₆-alkyl. In some embodiments, Y is —(CH₂)₁₋₂OC(O)N(H)— or—(CH₂)₁₋₂N(H)—. In some embodiments, Y is —O—.

In some embodiments, Y and Z together are a bond.

In some embodiment, X¹ is —OH, methyl, F, Br or Cl.

In some embodiments, X² is F, Cl or Br.

In some embodiments, X³ is F, Cl or Br.

In some embodiments, Z is —S(O)₂—. In some embodiments, Z is a bond. Insome embodiments, Z is ethenyl, ethynyl, methylene, ethylene, orpropylene. In some embodiments, Z, together with the nitrogen to which Zis attached forms a —C₂₋₆-heterocyloalkyl.

In some embodiments, R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(C₁₋₃-alkyl)(C₁₋₃-alkyl), —C(O)O—(C₁₋₆-alkyl), —N(H)C(O)—(C₁₋₆-alkyl),or —C₁₋₃-alkyl. In some embodiments, R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(H)C(O)—(C₁₋₆-alkyl), or —C₁₋₃-alkyl. In some embodiments, R ispyridinyl, phenyl, halophenyl, methoxyphenyl, monohalomethoxyphenyl,diihalomethoxyphenyl, trihalomethoxyphenyl, monohalomethyl,dihalomethyl, trihalomethyl, thienyl, halothienyl, thiazolyl,benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl, oxydiaryl (e.g.,oxydiphenyl, oxydinaphthalenyl, or phenoxynaphthalenyl). In someembodiments, R is —C₂₋₆-heterocyloalkyl unsubstituted or substitutedwith one or more of —C₁₋₆-alkyl, halo, benzyl, halobenzyl, pyridinyl,carbonyl, monohalomethyl, dihalomethyl, trihalomethyl, or—C(O)O—(C₁₋₆-alkyl).

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (2):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (3):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (4):

or a pharmaceutically acceptable salt thereof;

wherein

R—Z—N(R^(N1)) is —C₂₋₆-heterocyloalkyl unsubstituted or substituted withone or more of —C₁₋₆-alkyl, halo, phenyl, halophenyl, benzyl,halobenzyl, pyridinyl, carbonyl, monohalomethyl, dihalomethyl,trihalomethyl, or —C(O)O—(C₁₋₆-alkyl).

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (5):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (6):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (7):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (8):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (9):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (10):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1) is a compoundof Formula (11):

or a pharmaceutically acceptable salt thereof.

In another aspect, provided herein are compounds of Formula (1′):

or a pharmaceutically acceptable salt thereof;

wherein

Y is —(CH₂)₁₋₂N(H)— or —C(O)N(H)— (i.e. an amide);

X¹ is H, —OH, —C₁₋₃-alkyl (e.g., methyl), or halogen (e.g., F, Br orCl);

X² is H or halogen (e.g., F, Cl or Br);

X³ is H, —C₁₋₃-alkyl (e.g., methyl), or halogen (e.g., F, Cl or Br);

Z is a bond, ethenyl, ethynyl, methylene, ethylene, or propylene, or Z,together with the nitrogen to which Z is attached forms a—C₂₋₆-heterocyloalkyl; and

R is —OH, —NH₂, —NH(C₁₋₃-alkyl), —N(C₁₋₃-alkyl)(C₁₋₃-alkyl),—C(O)O—(C₁₋₆-alkyl), —N(H)C(O)—(C₁₋₆-alkyl), —C₁₋₃-alkyl, pyridinyl,phenyl, halophenyl, methoxyphenyl, monohalomethoxyphenyl,diihalomethoxyphenyl, trihalomethoxyphenyl, monohalomethyl,dihalomethyl, trihalomethyl, thienyl, halothienyl, thiazolyl,benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl, oxydiaryl (e.g.,oxydiphenyl, oxydinaphthalenyl, or phenoxynaphthalenyl), or R is—C₂₋₆-heterocyloalkyl unsubstituted or substituted with one or more of—C₁₋₆-alkyl, halo, benzyl, halobenzyl, pyridinyl, carbonyl,monohalomethyl, dihalomethyl, trihalomethyl, or —C(O)O—(C₁₋₆-alkyl);

or Y and Z together are a bond, and R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(C₁₋₃-alkyl)(C₁₋₃-alkyl), —N(H)C(O)—(C₁₋₆-alkyl), —C(O)NH₂,—C₁₋₃-alkyl, pyridinyl, phenyl, halophenyl, methoxyphenyl,monohalomethoxyphenyl, diihalomethoxyphenyl, trihalomethoxyphenyl,monohalomethyl, dihalomethyl, trihalomethyl, thienyl, halothienyl,thiazolyl, benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl,oxydiaryl (e.g., oxydiphenyl, oxydinaphthalenyl, orphenoxynaphthalenyl), or R is —C₂₋₆-heterocyloalkyl unsubstituted orsubstituted with one or more of —C₁₋₆-alkyl, halo, benzyl, halobenzyl,pyridinyl, carbonyl, monohalomethyl, dihalomethyl, trihalomethyl, or—C(O)O—(C₁₋₆-alkyl).

In some embodiments, Y is —C(O)N(H)— (i.e. an amide). In someembodiments, Y is —C(O)O— (i.e. an ester). In some embodiments, Y is—C₁₋₆-alkyl. In some embodiments, Y is —(CH₂)₁₋₂OC(O)N(H)— or—(CH₂)₁₋₂N(H)—. In some embodiments, Y is —O—.

In some embodiments, Y and Z together are a bond.

In some embodiment, X¹ is —OH, methyl, F, Br or Cl.

In some embodiments, X² is F, Cl or Br.

In some embodiments, X³ is F, Cl or Br.

In some embodiments, Z is —S(O)₂—. In some embodiments, Z is a bond. Insome embodiments, Z is ethenyl, ethynyl, methylene, ethylene, orpropylene. In some embodiments, Z, together with the nitrogen to which Zis attached forms a —C₂₋₆-heterocyloalkyl.

In some embodiments, R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(C₁₋₃-alkyl)(C₁₋₃-alkyl), —C(O)O—(C₁₋₆-alkyl), —N(H)C(O)—(C₁₋₆-alkyl),or —C₁₋₃-alkyl. In some embodiments, R is —OH, —NH₂, —NH(C₁₋₃-alkyl),—N(H)C(O)—(C₁₋₆-alkyl), or —C₁₋₃-alkyl. In some embodiments, R ispyridinyl, phenyl, halophenyl, methoxyphenyl, monohalomethoxyphenyl,diihalomethoxyphenyl, trihalomethoxyphenyl, monohalomethyl,dihalomethyl, trihalomethyl, thienyl, halothienyl, thiazolyl,benzothiophenyl, isoquinolinyl, —C₂₋₆-heterocyloalkyl, oxydiaryl (e.g.,oxydiphenyl, oxydinaphthalenyl, or phenoxynaphthalenyl). In someembodiments, R is —Cm-heterocyloalkyl unsubstituted or substituted withone or more of —C₁₋₆-alkyl, halo, benzyl, halobenzyl, pyridinyl,carbonyl, monohalomethyl, dihalomethyl, trihalomethyl, or—C(O)O—(C₁₋₆-alkyl).

In some embodiments, provided the compound of Formula (1′) is a compoundof Formula (12):

or a pharmaceutically acceptable salt thereof.

In some embodiments, provided the compound of Formula (1′) is a compoundof Formula (13):

or a pharmaceutically acceptable salt thereof.

In some embodiments of the Formulae provided herein, the compound is acompound provided in Table 1, Table 2, Table 3, Table 4, Table 5, Table6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 13,Table 14, Table 15, Table 16, Table 17 or Table 18, or apharmaceutically acceptable salt thereof.

Isomers

Compounds described herein may exist in one or more particulargeometric, optical, enantiomeric, diastereomeric, epimeric, atropic,stereoisomer, tautomeric, conformational, or anomeric forms, includingbut not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, andr-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d-and 1-forms; (+) and (−) forms; keto-, enol-, and enolate-forms; syn-and anti-forms; synclinal- and anticlinal-forms; α- and β-forms; axialand equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referredto as “isomers” (or “isomeric forms”).

In one embodiment, a compound described herein may be anenantiomerically enriched isomer of a stereoisomer described herein. Forexample, the compound may have an enantiomeric excess of at least about10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. Enantiomer, when used herein,refers to either of a pair of chemical compounds whose molecularstructures have a mirror-image relationship to each other.

In one embodiment, a preparation of a compound disclosed herein isenriched for an isomer of the compound having a selectedstereochemistry, e.g., R or S, corresponding to a selected stereocenter.For example, the compound has a purity corresponding to a compoundhaving a selected stereochemistry of a selected stereocenter of at leastabout 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

In one embodiment, a composition described herein includes a preparationof a compound disclosed herein that is enriched for a structure orstructures having a selected stereochemistry, e.g., R or S, at aselected stereocenter. Exemplary R/S configurations can be thoseprovided in an example described herein.

An “enriched preparation,” as used herein, is enriched for a selectedstereoconfiguration of one, two, three or more selected stereocenterswithin the subject compound. Exemplary selected stereocenters andexemplary stereoconfigurations thereof can be selected from thoseprovided herein, e.g., in an example described herein. By enriched ismeant at least 60%, e.g., of the molecules of compound in thepreparation have a selected stereochemistry of a selected stereocenter.In an embodiment it is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, or 99%. Enriched refers to the level of a subject molecule(s)and does not connote a process limitation unless specified.

Compounds may be prepared in racemic form or as individual enantiomersor diastereomers by either stereospecific synthesis or by resolution.The compounds may, for example, be resolved into their componentenantiomers or diastereomers by standard techniques, such as theformation of stereoisomeric pairs by salt formation with an opticallyactive base, followed by fractional crystallization and regeneration ofthe free acid. The compounds may also be resolved by formation ofstereoisomeric esters or amides, followed by chromatographic separationand removal of the chiral auxiliary. Alternatively, the compounds may beresolved using a chiral chromatography column. The enantiomers also maybe obtained from kinetic resolution of the racemate of correspondingesters using lipase enzymes.

Except as discussed below for tautomeric forms, specifically excludedfrom the term “isomers,” as used herein, are structural (orconstitutional) isomers (i.e., isomers which differ in the connectionsbetween atoms rather than merely by the position of atoms in space). Forexample, a reference to a methoxy group, —OCH₃, is not to be construedas a reference to its structural isomer, a hydroxymethyl group, —CH₂OH.Similarly, a reference to ortho-chiorophenyl is not to be construed as areference to its structural isomer, meta-chlorophenyl. However, areference to a class of structures may well include structurallyisomeric forms falling within that class (e.g., C₃-alkyl or propylincludes n-propyl and iso-propyl; Ca-alkyl or butyl includes n-, iso-,sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, andpara-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example,keto-, enol-, and enolate-forms, as in, for example, the followingtautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol,amidine/amidine, nitroso/oxime, thioketone/enethiol,N-nitroso/hydroxyazo, and nitro/aci-nitro.

Note that specifically included in the term “isomer” are compounds withone or more isotopic substitutions. For example, H may be in anyisotopic form, including ¹H, ²H (D), and ³H (T); C may be in anyisotopic form, including ¹²C, ¹³C, and ¹⁴C; O may be in any isotopicform, including ¹⁶O and ¹³O; and the like.

Salts

A compound described herein can be in the form of a salt, e.g., apharmaceutically acceptable salt. The term “pharmaceutically acceptablesalt” includes salts of the active compounds that are prepared withrelatively nontoxic acids or bases, depending on the particularsubstituents found on the compounds described herein. Neutral forms ofthe compounds may be regenerated by contacting the salt with a base oracid and isolating the parent compound in a conventional manner. Theparent form of the compound differs from the various salt forms incertain physical properties, such as solubility in polar solvents, butotherwise the salts are equivalent to the parent form of the compoundfor the purposes of this disclosure. Examples of pharmaceuticallyacceptable salts are discussed in Berge et al, 1977, “PharmaceuticallyAcceptable Salts.” J. Pharm. Sci. Vol. 66, pp. 1-19. In an embodiment,the compound is present in mono-salt form. In embodiments, the compoundis present in di-salt form.

For example, if the compound is anionic, or has a functional group whichmay be anionic (e.g., —COOH may be —COO⁻), then a salt may be formedwith a suitable cation. Examples of suitable inorganic cations include,but are not limited to, alkali metal ions such as Na⁺ and K⁺, alkalineearth cations such as Ca²⁺ and Mg²⁺, and other cations. Examples ofsuitable organic cations include, but are not limited to, ammonium ion(i.e., NH₄ ⁺) and substituted ammonium ions (e.g., NH₃R₁*, NH₂R₂ ⁺, NHR₃⁺, NR₄ ⁺). Examples of some suitable substituted ammonium ions are thosederived from: ethylamine, diethylamine, triethylamine, butylamine,ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine,phenylbenzylamine, choline, meglumine, and tromethamine, as well asdibasic amino acids, such as lysine and arginine.

If the compound is cationic, or has a functional group that may becationic (e.g., —NH₂ may be —NH₃ ⁺), then a salt may be formed with asuitable anion. Examples of suitable inorganic anions include, but arenot limited to, those derived from the following inorganic acids:hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric,nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited to,those derived from the following organic acids: 2-acetyoxybenzoic,acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric,edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic,gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalenecarboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic,methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic,phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic,succinic, sulfanilic, tartaric, p-toluenesulfonic, and valeric. Examplesof suitable polymeric organic anions include, but are not limited to,those derived from the following polymeric acids: tannic acid,carboxymethyl cellulose.

Unless otherwise specified, a reference to a particular compound alsoincludes salt forms thereof.

Chemically Protected Forms

It may be convenient or desirable to prepare, purify, and/or handle anactive compound in a chemically protected form. The term “chemicallyprotected form” is used herein in the conventional chemical sense andpertains to a compound in which one or more reactive functional groupsare protected from undesirable chemical reactions under specifiedconditions (e.g., pH, temperature, radiation, solvent, and the like). Inpractice, well known chemical methods are employed to reversibly renderunreactive a functional group, which otherwise would be reactive, underspecified conditions. In a chemically protected form, one or morereactive functional groups are in the form of a protected or protectinggroup (also known as a masked or masking group or a blocked or blockinggroup). By protecting a reactive functional group, reactions involvingother unprotected reactive functional groups can be performed, withoutaffecting the protected group; the protecting group may be removed,usually in a subsequent step, without substantially affecting theremainder of the molecule. See, for example, Protective Groups inOrganic Synthesis (T. Green and P. Wuts; 3rd Edition; John Wiley andSons, 1999). Unless otherwise specified, a reference to a particularcompound also includes chemically protected forms thereof.

A wide variety of such “protecting,” “blocking,” or “masking” methodsare widely used and well known in organic synthesis. For example, acompound which has two nonequivalent reactive functional groups, both ofwhich would be reactive under specified conditions, may be derivatizedto render one of the functional groups “protected,” and thereforeunreactive, under the specified conditions; so protected, the compoundmay be used as a reactant which has effectively only one reactivefunctional group. After the desired reaction (involving the otherfunctional group) is complete, the protected group may be “deprotected”to return it to its original functionality.

A hydroxyl group may be protected as an ether (—OR) or an ester(—OC(O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl(diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl ort-butyldimethylsilyl ether; or an acetyl ester (—OC(O)CH₃, —OAc).

An aldehyde or ketone group may be protected as an acetal (RCH(OR)₂) orketal (R₂C(OR)₂), respectively, in which the carbonyl group (R₂C═O) isconverted to a diether (R₂C(OR)₂), by reaction with, for example, aprimary alcohol. The aldehyde or ketone group is readily regenerated byhydrolysis using a large excess of water in the presence of acid.

An amine group may be protected, for example, as an amide (—NRC(O)R) ora urethane (—NRC(O)OR), for example, as: a methyl amide (—NHC(O)CH₃); abenzyloxy amide (—NHC(O)OCH₂C₆H₅, —NH-Cbz); as a tert-butoxy amide(—NHC(O)OC(CH₃)₃, —NH-Boc); a 2-biphenyl-2-propoxy amide(—NHCO(O)C(CH₃)₂C₆H₄C₆H₅, —NH-Bpoc), as a 9-fluorenylmethoxy amide(—NH—Fmoc), as a 6-nitroveratryloxy amide (—NH—Nvoc), as a2-trimethylsilylethyloxy amide (—NH-Teoc), as a 2,2,2-trichloroethyloxyamide (—NH-Troc), as an allyloxy amide (—NH-Alloc), as a2(-phenylsulphonyl)ethyloxy amide (—NH—Psec); or, in suitable cases(e.g., cyclic amines), as a nitroxide radical (>N—O<<).

A carboxylic acid group may be protected as an ester, for example, as:an alkyl ester (e.g., a methyl ester; a t-butyl ester); a haloalkylester (e.g., a haloalkyl ester); a trialkylsilylalkyl ester; or anarylalkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as anamide, for example, as a methyl amide.

A thiol group may be protected as a thioether (—SR), for example, as: abenzyl thioether; an acetamidomethyl ether (—S—CH₂NHC(O)CH₃)

Prodrugs and Other Modifications

In addition to salt forms, the present disclosure may also providecompounds that are in a prodrug form. Prodrugs of the compoundsdescribed herein are those compounds that readily undergo chemicalchanges under physiological conditions to provide the compoundsdescribed herein. Prodrugs can be converted to the compounds of thepresent disclosure by chemical or biochemical methods in an ex vivoenvironment. For example, prodrugs can be slowly converted to thecompounds of the present disclosure when placed in a transdermal patchreservoir with or without a suitable enzyme or chemical reagent.

A compound described herein can also be modified by appendingappropriate functionalities to enhance selective biological properties.Such modifications are known in the art and include those that increasebiological penetration into a given biological system (e.g., blood,lymphatic system, central nervous system), increase oral availability,increase solubility to allow administration by injection, altermetabolism, and/or alter rate of excretion. Examples of thesemodifications include, but are not limited to, esterification withpolyethylene glycols, derivatization with pivolates or fatty acidsubstituents, conversion to carbamates, hydroxylation of aromatic rings,and heteroatom substitution in aromatic rings.

Synthesis

The compounds may be synthesized according to the exemplary synthesesshown in the Examples.

Other methods of synthesizing the compounds of the formulae herein willbe evident to those of ordinary skill in the art. Synthetic chemistrytransformations and protecting group methodologies (protection anddeprotection) useful in synthesizing the compounds are known in the artand include, for example, those such as described in R. Larock,Comprehensive Organic Transformations, VCH Publishers (1989); T. W.Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d.Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser andFieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); andL. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, JohnWiley and Sons (1995), and subsequent editions thereof.

Methods of Use and Activity

The compounds as disclosed herein and compositions including them havekinase inhibitory activity and are thus useful in modulating the actionof kinases, and in treatment and/or prevention of diseases or conditionsinfluenced by kinases. The above compounds and compositions may be usedto modulate (e.g., influence or inhibit) the action of kinases either ina cell in vitro or in a cell in a living body in vivo. Specifically, inone embodiment, a method is provided of inhibiting the action of akinase comprising applying to a medium such as an assay medium orcontacting with a cell either in a cell in vitro or in a cell in aliving body in vivo an effective inhibitory amount of a compound asdisclosed herein. In one embodiment, the kinase inhibited is a rhokinase. In another embodiment, the kinase inhibited is a JAK (e.g.,JAK2) kinase.

JAK inhibitors are useful in treating various JAK-associated diseases ordisorders. Examples of JAK-associated diseases include diseasesinvolving the immune system including, for example, organ transplantrejection (e.g., allograft rejection and graft versus host disease).Further examples of JAK-associated diseases include autoimmune diseasessuch as multiple sclerosis, rheumatoid arthritis, juvenile arthritis,psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatorybowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis,immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorders,chronic obstructive pulmonary disease (COPD), and the like. In someembodiments, the autoimmune disease is arthritis.

Further examples of JAK-associated diseases include allergic conditionssuch as asthma, food allergies, eczematous dermatitis, contactdermatitis, atopic dermatitis (atropic eczema), and rhinitis. Furtherexamples of JAK-associated diseases include viral diseases such asEpstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1,Varicella-Zoster Virus (VZV) and Human Papilloma Virus (HPV).

Further examples of JAK-associated diseases or conditions include thosecharacterized by solid tumors (e.g., prostate cancer, renal cancer,hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lungcancer, cancers of the head and neck, thyroid cancer, glioblastoma,Kaposi's sarcoma, Castleman's disease, uterine leiomyosarcoma, melanomaetc.), hematological cancers (e.g., lymphoma, leukemia such as acutelymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) ormultiple myeloma), and skin cancer such as cutaneous T-cell lymphoma(CTCL) and cutaneous B-cell lymphoma. Example CTCLs include Sezarysyndrome and mycosis fungoides. Other examples of JAK-associateddiseases or conditions include pulmonary arterial nypertension.

Other examples of JAK-associated diseases or conditions includeinflammation-associated cancers. In some embodiments, the cancer isassociated with inflammatory bowel disease. In some embodiments, theinflammatory bowel disease is ulcerative colitis. In some embodiments,the inflammatory bowel disease is Crohn's disease. In some embodiments,the inflammation-associated cancer is colitis-associated cancer. In someembodiments, the inflammation-associated cancer is colon cancer orcolorectal cancer. In some embodiments, the cancer is gastric cancer,gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST),adenocarcinoma, small intestine cancer, or rectal cancer.

The compounds of the present disclosure are used in methods ofinhibiting kinases in a cell, a tissue or a subject such as a humancomprising contacting the cell with an amount of one or more of thecompounds of the present disclosure effective to inhibit the kinase. Inone embodiment, the compounds are administered in a pharmaceuticallyacceptable composition, such as in or with a pharmaceutically acceptablecarrier.

In another embodiment, the compounds of the present disclosure are usedin methods for modulating the action of a kinase in a cell comprisingcontacting the cell with amount of one or more compounds of the presentdisclosure effective to modulate the action of a kinase in a cell. Inone embodiment, the compounds of the present disclosure are administeredin a pharmaceutically acceptable composition, such as in or with apharmaceutically acceptable carrier.

Treatment or prevention of diseases or conditions for which thecompounds of the present disclosure may be useful includes any of thediseases or conditions associated with kinase activity or diseases orconditions affected by kinases. Examples of these types of diseasesinclude neurodegenerative diseases, such as Alzheimer's; oculardiseases, such as diabetic eye diseases, wet age-related maculardegeneration, or dry age-related macular degeneration, inflammatory eyediseases, retinal degradation and glaucoma; cardiovascular diseases; andcancer. Additional examples include bone disorder, obesity, hepaticdisease, renal disease, pancreatitis, gastric disturbance, hypertension,fertility control, disorders of hair growth, nasal congestion,neurogenic bladder disorder, gastrointestinal disorder, dermatologicaldisorder, and respiratory indications.

In some embodiments, the compounds of the present disclosure will beadministered in conjunction with one or more additional therapeuticagents. Suitable classes of additional therapeutic agents include, butare not limited to, beta blockers, alpha-agonists, carbonic anhydraseinhibitors, prostaglandin-like compounds, miotic or cholinergic agents,epinephrine compounds, or neuroprotective or anti-inflammatorycompounds.

Beta blockers. These compounds are thought to lower intraocular pressure(IOP) by reducing the production of aqueous humor. Examples includelevobunolol (BETAGAN™), timolol (BETIMOL™, TIMOPTIC™), betaxolol(BETOPTIC™) and metipranolol (OPTIPRANOLOL™).

Alpha-agonists. These compounds are thought to lower IOP by reducing theproduction of aqueous humor and increasing drainage. Examples includeapraclonidine (IOPIDINE™) and brimonidine (ALPHAGAN™)

Carbonic anhydrase inhibitors. These compounds are thought to lower IOPby also reducing the production of aqueous humor. Examples includedorzolamide (TRUSOPT™) and brinzolamide (AZOPT™).

Prostaglandin-like compounds. These compounds are thought to lower IOPby increasing the outflow of aqueous humor by the uveoscieral pathway.Examples include AR-102, latanoprost (XALATAN™), bimatoprost (LUMIGAN™),tafluprost (ZIOPTAN™), and travoprost (TRAVATAN™).

Miotic or cholinergic agents. These agents are thought to function bycausing the pupil to constrict, which opens drainage channels in theeye. Examples include pilocarpine (ISOPTO CARPINE™, PILOPINE™) andcarbachol (ISOPTO CARBACHOL™)

Epinephrine compounds. These compounds, such as dipivefrin (PROPINE™),are thought to function by both decreasing the outflow of aqueous humor,as well as increasing fluid drainage.

Neuroprotective or anti-inflammatory compounds. These compounds, such asAflibercept (EYLEA™) are treatments for conditions of the retina such asMacular Degeneration, and are designed as anti-VEGF treatments or havesimilar types of anti-growth or anti-inflammatory activity.

Thus, provided herein are methods of treating an ocular disorder in asubject in need thereof, comprising administering to the subject acompound, a composition, or a pharmaceutical composition providedherein.

Also provided herein are methods of reducing intraocular pressure in asubject in need thereof, comprising administering to the subject acompound, a composition, or a pharmaceutical composition providedherein.

In one aspect, provided herein are methods of treating an oculardisorder in a subject in need thereof, comprising administering to thesubject a compound, or a pharmaceutically acceptable salt thereof,provided herein.

In some embodiments, the ocular disorder is glaucoma.

In another aspect, provided herein are methods of reducing intraocularpressure in a subject in need thereof, comprising administering to thesubject a compound, or a pharmaceutically acceptable salt thereof,provided herein.

In some embodiments of these aspects, the compound is administeredtopically to an eye of the subject.

In some embodiments, provided herein are methods of treating an oculardisorder in a subject in need thereof, comprising administering to thesubject a compound of any of the Formulae provided herein, or apharmaceutically acceptable salt thereof.

In some embodiments, provided herein are methods of treating an oculardisorder in a subject in need thereof, comprising administering to thesubject a compound provided in Table 1, Table 2, Table 3, Table 4, Table5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12,Table 13, Table 14, Table 15, Table 16, Table 17 or Table 18, orapharmaceutically acceptable salt thereof.

In some embodiments, provided herein are methods of reducing intraocularpressure in a subject in need thereof, comprising administering to thesubject a compound of any of the Formulae provided herein, or apharmaceutically acceptable salt thereof.

In some embodiments, provided herein are methods of reducing intraocularpressure in a subject in need thereof, comprising administering to thesubject a compound provided in Table 1, Table 2, Table 3, Table 4, Table5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12,Table 13, Table 14, Table 15, Table 16, Table 17 or Table 18, or apharmaceutically acceptable salt thereof.

In some embodiments of these methods, the method further comprisesadministering one or more additional therapeutic agents. In someembodiments, the one or more additional therapeutic agents is a betablocker, an alpha-agonist, a carbonic anhydrase inhibitor, aprostaglandin or a prostaglandin-like compound, a miotic or cholinergicagent, an epinephrine compound, or a neuroprotective oranti-inflammatory compound. In some embodiments, the one or moreadditional therapeutic agents is a prostaglandin or a prostaglandin-likecompound. In some embodiment, the prostaglandin-like compound is AR-102,latanoprost, bimatoprost, tafluprost, or travoprost.

Also provided herein are methods of treating an autoimmune disease in asubject in need thereof, comprising administering to the subject acompound, a composition, or a pharmaceutical composition providedherein.

In some embodiments, provided herein are methods of treating anautoimmune disease in a subject in need thereof, comprisingadministering to the subject a compound of any of the Formulae providedherein, or a pharmaceutically acceptable salt thereof.

In some embodiments, provided herein are methods of treating anautoimmune disease in a subject in need thereof, comprisingadministering to the subject a compound provided in Table 1, Table 2,Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10,Table 11, Table 12, Table 13, Table 14, Table 15, Table 16, Table 17 orTable 18, or a pharmaceutically acceptable salt thereof.

In some embodiments, the autoimmune disease is multiple sclerosis,rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type Idiabetes, lupus, psoriasis, inflammatory bowel disease, ulcerativecolitis, Crohn's disease, myasthenia gravis, immunoglobulinnephropathies, myocarditis, autoimmune thyroid disorders, or chronicobstructive pulmonary disease.

Compositions and Administration

The additional therapeutic agent or agents can be administeredsimultaneously or sequentially with the compounds of the presentdisclosure. Sequential administration includes administration before orafter the compounds of the present disclosure. In some embodiments, theadditional therapeutic agent or agents can be administered in the samecomposition as the compounds of the present disclosure. In otherembodiments, there can be an interval of time between administration ofthe additional therapeutic agent and the compounds of the presentdisclosure.

In some embodiments, the administration of an additional therapeuticagent with a compound of the present disclosure will enable lower dosesof the other therapeutic agents to be administered for a longer periodof time.

Also provided herein are compositions comprising a compound providedherein, or a pharmaceutically acceptable salt thereof. In oneembodiment, the compositions provided herein are pharmaceuticalcompositions comprising a pharmaceutically acceptable carrier.

Pharmaceutical compositions for use in accordance with the presentdisclosure may be formulated in a conventional manner using one or morephysiologically acceptable carriers or excipients. Thus, the compoundsand their physiologically acceptable salts and solvates may beformulated for administration by, for example, solid dosing, eyedrop, ina topical oil-based formulation, injection (including injection of adrug-eluting device either into the body as a whole, or into specifictissues of the eye), inhalation (either through the mouth or the nose),implants, or oral, buccal, parenteral or rectal administration.Techniques and formulations may generally be found in “Remington'sPharmaceutical Sciences,” (Meade Publishing Co., Easton, Pa.).

The route by which the compounds of the present disclosure (component A)will be administered and the form of the composition will dictate thetype of carrier (component B) to be used. The composition may be in avariety of forms, suitable, for example, for systemic administration(e.g., oral, rectal, nasal, sublingual, buccal, implants, or parenteral,or by ocular injection into one of the chambers of the eye, such asintravitreal injection, intracameral injection, or injection into theaqueous humour.) or topical administration (e.g., local application onthe skin, ocular, liposome delivery systems, or iontophoresis).

Carriers for systemic administration typically comprise at least one ofa) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants,f) flavors, g) sweeteners, h) antioxidants, j) preservatives, k)glidants, m) solvents, n) suspending agents, o) wetting agents, p)surfactants, combinations thereof, and others. All carriers are optionalin the systemic compositions.

Ingredient a) is a diluent. Suitable diluents for solid dosage formsinclude sugars such as glucose, lactose, dextrose, and sucrose; diolssuch as propylene glycol; calcium carbonate; sodium carbonate; sugaralcohols, such as glycerin; mannitol; and sorbitol. The amount ofingredient a) in the systemic or topical composition is typically about50 to about 90%.

Ingredient b) is a lubricant. Suitable lubricants for solid dosage formsare exemplified by solid lubricants including silica, talc, stearic acidand its magnesium salts and calcium salts, calcium sulfate; and liquidlubricants such as polyethylene glycol and vegetable oils such as peanutoil, cottonseed oil, sesame oil, olive oil, corn oil and oil ofTheobroma. The amount of ingredient b) in the systemic or topicalcomposition is typically about 5 to about 10%.

Ingredient c) is a binder. Suitable binders for solid dosage formsinclude polyvinyl pyrrolidone; magnesium aluminum silicate; starchessuch as corn starch and potato starch; gelatin; tragacanth; andcellulose and its derivatives, such as sodium carboxymethylcellulose,ethyl cellulose, methylcellulose, microcrystalline cellulose, and sodiumcarboxymethylcellulose. The amount of ingredient c) in the systemiccomposition is typically about 5 to about 50%, and in ocular soliddosing forms up to 99%.

Ingredient d) is a disintegrant. Suitable disintegrants for solid dosageforms include agar, alginic acid and the sodium salt thereof,effervescent mixtures, croscarmelose, crospovidone, sodium carboxymethylstarch, sodium starch glycolate, clays, and ion exchange resins. Theamount of ingredient d) in the systemic or topical composition istypically about 0.1 to about 10%.

Ingredient e) for solid dosage forms is a colorant such as an FD&C dye.When used, the amount of ingredient e) in the systemic or topicalcomposition is typically about 0.005 to about 0.1%.

Ingredient f) for solid dosage forms is a flavor such as menthol,peppermint, and fruit flavors. The amount of ingredient f), when used,in the systemic or topical composition is typically about 0.1 to about1.0%.

Ingredient g) for solid dosage forms is a sweetener such as aspartameand saccharin. The amount of ingredient g) in the systemic or topicalcomposition is typically about 0.001 to about 1%.

Ingredient h) is an antioxidant such as butylated hydroxyanisole(“BHA”), butylated hydroxytoluene (“BHT”), and vitamin E. The amount ofingredient h) in the systemic or topical composition is typically about0.1 to about 5%.

Ingredient j) is a preservative such as benzalkonium chloride, methylparaben and sodium benzoate. The amount of ingredient j) in the systemicor topical composition is typically about 0.01 to about 5%.

Ingredient k) for solid dosage forms is a glidant such as silicondioxide. The amount of ingredient k) in the systemic or topicalcomposition is typically about 1 to about 5%.

Ingredient m) is a solvent, such as water, isotonic saline, ethyloleate, glycerine, hydroxylated castor oils, alcohols such as ethanol,and phosphate buffer solutions. The amount of ingredient m) in thesystemic or topical composition is typically from about 0 to about 100%.

Ingredient n) is a suspending agent. Suitable suspending agents includeAVICEL® RC-591 (from FMC Corporation of Philadelphia, Pa.) and sodiumalginate. The amount of ingredient n) in the systemic or topicalcomposition is typically about 1 to about 8%.

Ingredient o) is a surfactant such as lecithin, Polysorbate 80, andsodium lauryl sulfate, and the TWEENS® from Atlas Powder Company ofWilmington, Del. Suitable surfactants include those disclosed in theC.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington'sPharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon'sVolume 1, Emulsifiers & Detergents, 1994, North American Edition, pp.236-239. The amount of ingredient o) in the systemic or topicalcomposition is typically about 0.1% to about 5%.

Although the amounts of components A and B in the systemic compositionswill vary depending on the type of systemic composition prepared, thespecific derivative selected for component A and the ingredients ofcomponent B, in general, system compositions comprise 0.01% to 50% ofcomponent A and 50 to 99.99% of component B.

Compositions for parenteral administration typically comprise A) 0.1 to10% of the compounds of the present disclosure and B) 90 to 99.9% of acarrier comprising a) a diluent and m) a solvent. In one embodiment,component a) comprises propylene glycol and m) comprises ethanol orethyl oleate.

Compositions for oral administration can have various dosage forms. Forexample, solid forms include tablets, capsules, granules, and bulkpowders. These oral dosage forms comprise a safe and effective amount,usually at least about 5%, and more particularly from about 25% to about50% of component A). The oral dosage compositions further comprise about50 to about 95% of component B), and more particularly, from about 50 toabout 75%.

Tablets can be compressed, tablet triturates, enteric-coated,sugar-coated, film-coated, or multiple-compressed. Tablets typicallycomprise component A, and component B a carrier comprising ingredientsselected from the group consisting of a) diluents, b) lubricants, c)binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, k)glidants, and combinations thereof. Specific diluents include calciumcarbonate, sodium carbonate, mannitol, lactose and cellulose. Specificbinders include starch, gelatin, and sucrose. Specific disintegrantsinclude alginic acid and croscarmelose. Specific lubricants includemagnesium stearate, stearic acid, and talc. Specific colorants are theFD&C dyes, which can be added for appearance. Chewable tabletspreferably contain g) sweeteners such as aspartame and saccharin, or f)flavors such as menthol, peppermint, fruit flavors, or a combinationthereof.

Capsules (including implants, time release and sustained releaseformulations) typically comprise component A, and a carrier comprisingone or more a) diluents disclosed above in a capsule comprising gelatin.Granules typically comprise component A, and preferably further comprisek) glidants such as silicon dioxide to improve flow characteristics.Implants can be of the biodegradable or the non-biodegradable type.Implants may be prepared using any known biocompatible formulation.

The selection of ingredients in the carrier for oral compositionsdepends on secondary considerations like taste, cost, and shelfstability, which are not critical for the purposes of this disclosure.One skilled in the art would know how to select appropriate ingredientswithout undue experimentation.

The solid compositions may also be coated by conventional methods,typically with pH or time-dependent coatings, such that component A isreleased in the gastrointestinal tract in the vicinity of the desiredapplication, or at various points and times to extend the desiredaction. The coatings typically comprise one or more components selectedfrom the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethylcellulose, EUDRAGIT® coatings (available from Rohm & Haas G.M.B.H. ofDarmstadt, Germany), waxes and shellac.

Compositions for oral administration can also have liquid forms. Forexample, suitable liquid forms include aqueous solutions, emulsions,suspensions, solutions reconstituted from non-effervescent granules,suspensions reconstituted from non-effervescent granules, effervescentpreparations reconstituted from effervescent granules, elixirs,tinctures, syrups, and the like. Liquid orally administered compositionstypically comprise component A and component B, namely, a carriercomprising ingredients selected from the group consisting of a)diluents, e) colorants, f) flavors, g) sweeteners, j) preservatives, m)solvents, n) suspending agents, and o) surfactants. Peroral liquidcompositions preferably comprise one or more ingredients selected fromthe group consisting of e) colorants, f) flavors, and g) sweeteners.

Other compositions useful for attaining systemic delivery of the subjectcompounds include injection, sublingual, buccal and nasal dosage forms.Such compositions typically comprise one or more of soluble fillersubstances such as a) diluents including sucrose, sorbitol and mannitol;and c) binders such as acacia, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropyl methylcellulose. Such compositions mayfurther comprise b) lubricants, e) colorants, f) flavors, g) sweeteners,h) antioxidants, and k) glidants.

In one embodiment of the disclosure, the compounds of the presentdisclosure are topically administered. Topical compositions that can beapplied locally to the eye may be in any form known in the art,non-limiting Examples of which include solids, gelable drops, sprays,ointments, or a sustained or non-sustained release unit placed in theconjunctival cul-du-sac of the eye or another appropriate location.

Topical compositions that can be applied locally to the skin may be inany form including solids, solutions, oils, creams, ointments, gels,lotions, shampoos, leave-on and rinse-out hair conditioners, milks,cleansers, moisturizers, sprays, skin patches, and the like. Topicalcompositions comprise: component A, the compounds described above, andcomponent B, a carrier. The carrier of the topical compositionpreferably aids penetration of the compounds into the eye. Component Bmay further comprise one or more optional components.

An effective amount of a compound according to the present disclosurewill vary with the particular condition being treated, the age andphysical condition of the patient being treated, the severity of thecondition, the duration of treatment, the nature of concurrent therapy,the route of administration, the particular pharmaceutically-acceptablecarrier utilized, and like factors within the knowledge and expertise ofthe attending physician. For example, an effective amount of thecompounds of the present disclosure for systemic administration is fromabout 0.01 to about 1000 μg/kg body weight, preferably from about 0.1 toabout 100 μg/kg per body weight, most preferably form about 1 to about50 μg/kg body weight per day. The transdermal dosages will be designedto attain similar serum or plasma levels, based upon techniques known tothose skilled in the art of pharmacokinetics and transdermalformulations. Plasma levels for systemic administration are expected tobe in the range of 0.01 to 100 ng/mL, more preferably from 0.05 to 50ng/mL and most preferably from 0.1 to 10 ng/mL. While these dosages arebased upon a daily administration rate, the compounds of the presentdisclosure may also be administered at other intervals, such as twiceper day, twice weekly, once weekly, or once a month. One of ordinaryskill in the art would be able to calculate suitable effective amountsfor other intervals of administration.

The compounds of the present disclosure are useful in a method ofreducing or decreasing intraocular pressure. The compounds of thepresent disclosure may be administered to a subject in need of treatmentin an amount effective to reduce intraocular pressure. Thus, thesecompounds are useful in the treatment of glaucoma. The preferred routeof administration for treating glaucoma is topically.

The exact amounts of each component in the topical composition depend onvarious factors. The amount of component A added to the topicalcomposition is dependent on the IC₅₀ of component A, typically expressedin nanomolar (nM) units. For example, if the IC₅₀ of the medicament is 1nM, the amount of component A will be from about 0.001 to about 0.3%. Ifthe IC₅₀ of the medicament is 10 nM, the amount of component A) will befrom about 0.01 to about 1%. If the IC₅₀ of the medicament is 100 nM,the amount of component A will be from about 0.1 to about 10%. If theamount of component A is outside the ranges specified above (i.e.,lower), efficacy of the treatment may be reduced. One skilled in the artunderstands how to calculate and understand an IC₅₀. The remainder ofthe composition, up to 100%, is component B.

The amount of the carrier employed in conjunction with component A issufficient to provide a practical quantity of composition foradministration per unit dose of the medicament. Techniques andcompositions for making dosage forms useful in the methods of thisdisclosure are described in the following references: ModernPharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979);Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); andAnsel, Introduction to Pharmaceutical Dosage Forms, 2^(nd) Ed., (1976).

Component B may comprise a single ingredient or a combination of two ormore ingredients. In the topical compositions, component B comprises atopical carrier. Suitable topical carriers comprise one or moreingredients selected from the group consisting of phosphate bufferedsaline, isotonic water, deionized water, monofunctional alcohols,symmetrical alcohols, aloe vera gel, allantoin, glycerin, vitamin A andE oils, mineral oil, propylene glycol, PPG-2 myristyl propionate,dimethyl isosorbide, castor oil, combinations thereof, and the like.More particularly, carriers for skin applications include propyleneglycol, dimethyl isosorbide, and water, and even more particularly,phosphate buffered saline, isotonic water, deionized water,monofunctional alcohols and symmetrical alcohols.

The carrier of the topical composition may further comprise one or moreingredients selected from the group consisting of q) emollients, r)propellants, s) solvents, t) humectants, u) thickeners, v) powders, w)fragrances, x) pigments, and y) preservatives.

Ingredient q) is an emollient. The amount of ingredient q) in askin-based topical composition is typically about 5 to about 95%.Suitable emollients include stearyl alcohol, glyceryl monoricinoleate,glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil,cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate,isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate,decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate,di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropylstearate, butyl stearate, polyethylene glycol, triethylene glycol,lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylatedlanolin alcohols, petroleum, mineral oil, butyl myristate, isostearicacid, palmitic acid, isopropyl linoleate, lamyl lactate, myristyllactate, decyl oleate, myristyl myristate, and combinations thereof.Specific emollients for skin include stearyl alcohol andpolydimethylsiloxane.

Ingredient r) is a propellant. The amount of ingredient r) in thetopical composition is typically about 0 to about 95%. Suitablepropellants include propane, butane, isobutane, dimethyl ether, carbondioxide, nitrous oxide, and combinations thereof.

Ingredient s) is a solvent. The amount of ingredient s) in the topicalcomposition is typically about 0 to about 95%. Suitable solvents includewater, ethyl alcohol, methylene chloride, isopropanol, castor oil,ethylene glycol monoethyl ether, diethylene glycol monobutyl ether,diethylene glycol monoethyl ether, dimethylsulfoxide, dimethylformamide, tetrahydrofuran, and combinations thereof. Specific solventsinclude ethyl alcohol and homotopic alcohols.

Ingredient t) is a humectant. The amount of ingredient t) in the topicalcomposition is typically 0 to 95%. Suitable humectants include glycerin,sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutylphthalate, gelatin, and combinations thereof. Specific humectantsinclude glycerin.

Ingredient u) is a thickener. The amount of ingredient u) in the topicalcomposition is typically about 0 to about 95%.

Ingredient v) is a powder. The amount of ingredient v) in the topicalcomposition is typically 0 to 95%. Suitable powders includebeta-cyclodextrins, hydroxypropyl cyclodextrins, chalk, talc, fullersearth, kaolin, starch, gums, colloidal silicon dioxide, sodiumpolyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammoniumsmectites, chemically-modified magnesium aluminum silicate,organically-modified Montmorillonite clay, hydrated aluminum silicate,fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose,ethylene glycol monostearate, and combinations thereof. For ocularapplications, specific powders include beta-cyclodextrin, hydroxypropylcyclodextrin, and sodium polyacrylate. For gel dosing ocularformulations, sodium polyacrylate may be used.

Ingredient w) is a fragrance. The amount of ingredient w) in the topicalcomposition is typically about 0 to about 0.5%, particularly, about0.001 to about 0.1%. For ocular applications a fragrance is nottypically used.

Ingredient x) is a pigment. Suitable pigments for skin applicationsinclude inorganic pigments, organic lake pigments, pearlescent pigments,and mixtures thereof. Inorganic pigments useful in this disclosureinclude those selected from the group consisting of rutile or anatasetitanium dioxide, coded in the Color Index under the reference CI77,891; black, yellow, red and brown iron oxides, coded under referencesCI 77,499, 77,492 and, 77,491; manganese violet (CI 77,742); ultramarineblue (CI 77,007); chromium oxide (CI 77,288); chromium hydrate (CI77,289); and ferric blue (CI 77,510) and mixtures thereof.

The organic pigments and lakes useful in this disclosure include thoseselected from the group consisting of D&C Red No. 19 (CI 45,170), D&CRed No. 9 (CI 15,585), D&C Red No. 21 (CI 45,380), D&C Orange No. 4 (CI15,510), D&C Orange No. 5 (CI 45,370), D&C Red No. 27 (CI 45,410), D&CRed No. 13 (CI 15,630), D&C Red No. 7 (CI 15,850), D&C Red No. 6 (CI15,850), D&C Yellow No. 5 (CI 19,140), D&C Red No. 36 (CI 12,085), D&COrange No. 10 (CI 45,425), D&C Yellow No. 6 (CI 15,985), D&C Red No. 30(CI 73,360), D&C Red No. 3 (CI 45,430), the dye or lakes based onCochineal Carmine (CI 75,570) and mixtures thereof.

The pearlescent pigments useful in this disclosure include thoseselected from the group consisting of the white pearlescent pigmentssuch as mica coated with titanium oxide, bismuth oxychloride, coloredpearlescent pigments such as titanium mica with iron oxides, titaniummica with ferric blue, chromium oxide and the like, titanium mica withan organic pigment of the above-mentioned type as well as those based onbismuth oxychloride and mixtures thereof. The amount of pigment in thetopical composition is typically about 0 to about 10%. For ocularapplications a pigment is generally not used.

In a particularly preferred embodiment of the disclosure, topicalpharmaceutical compositions for ocular administration are preparedtypically comprising component A and B (a carrier), such as purifiedwater, and one or more ingredients selected from the group consisting ofy) sugars or sugar alcohols such as dextrans, particularly mannitol anddextran 70, z) cellulose or a derivative thereof, aa) a salt, bb)disodium EDTA (Edetate disodium), and cc) a pH adjusting additive.

Examples of z) cellulose derivatives suitable for use in the topicalpharmaceutical composition for ocular administration include sodiumcarboxymethylcellulose, ethylcellulose, methylcellulose, andhydroxypropyl-methylcellulose, particularly,hydroxypropyl-methylcellulose.

Examples of aa) salts suitable for use in the topical pharmaceuticalcomposition for ocular administration include mono-, di- and trisodiumphosphate, sodium chloride, potassium chloride, and combinationsthereof.

Examples of cc) pH adjusting additives include HCl or NaOH in amountssufficient to adjust the pH of the topical pharmaceutical compositionfor ocular administration to the range of 4.5-7.5 pH units.

Component A may be included in kits comprising a compound of Formulas(I)-(IX), a systemic or topical composition described above, or both;and information, instructions, or both that use of the kit will providetreatment for cosmetic and medical conditions in mammals (particularlyhumans). The information and instructions may be in the form of words,pictures, or both, and the like. In addition or in the alternative, thekit may comprise the medicament, a composition, or both; andinformation, instructions, or both, regarding methods of application ofmedicament, or of composition, preferably with the benefit of treatingor preventing cosmetic and medical conditions in mammals (e.g., humans).

The disclosure will be further explained by the following illustrativeExamples that are to be considered to be non-limiting.

EXAMPLES

All temperatures are given in degrees Centigrade. Reagents and startingmaterials were purchased from commercial sources or prepared followingpublished literature procedures.

Unless otherwise noted, HPLC purification, when appropriate, wasperformed by redissolving the compound in a small volume of DMSO andfiltering through a 0.45 micron (nylon disc) syringe filter. Thesolution was then purified using, for example, a 50 mm Varian Dynamax

HPLC 21.4 mm Microsorb Guard-8 C₈ column. A typical initial elutingmixture of 40-80% MeOH:H₂O was selected as appropriate for the targetcompound. This initial gradient was maintained for 0.5 minutes thenincreased to 100% MeOH:0% H₂O over 5 minutes. 100% MeOH was maintainedfor 2 more minutes before re-equilibration back to the initial startinggradient. A typical total run time was 8 minutes. The resultingfractions were analyzed, combined as appropriate, and then evaporated toprovide purified material.

Proton magnetic resonance (¹H NMR) spectra were recorded on either aBruker 600 MHz spectrometer equipped with a sample changer and acryoprobe, a Varian INOVA 600 MHz (¹H) NMR spectrometer, Varian INOVA500 MHz (¹H) NMR spectrometer, Varian Mercury 300 MHz (¹H) NMRspectrometer, or a Varian Mercury 200 MHz (¹H) NMR spectrometer. Allspectra were determined in the solvents indicated. Although chemicalshifts are reported in ppm downfield of tetramethylsilane, they arereferenced to the residual proton peak of the respective solvent peakfor ¹H NMR. Interproton coupling constants are reported in Hertz (Hz).

Analytical LCMS spectra were obtained using a Waters Acquity QDA MS ESIinstrument with an Alliance 2695 HPLC and a 2998 Photodiode ArrayDetector. Spectra were analyzed at 254 and 230 nm. Samples were passedthrough a Waters Atlantis T3 4.6×75 mm 3.5 μm column with a guard column(Atlantis T3 4.6×20 mm 5 μm. Gradients were typically run with mobilephase A: 0.1% formic acid in H₂O and mobile phase B: ACN with a flowrate of 0.8 mL/min. Two gradients will illustrate:

Gradient B Time A % B % 0.00 80.0 20.0 1.00 80.0 20.0 6.00 25.0 75.07.00 5.0 95.0 8.00 5.0 95.0 9.00 80.0 20.0 12.00 80.0 20.0

Gradient A Time A % B % 0.00 95 5.0 1.00 95 5.0 6.00 40 60 7.00 5.0 95.08.00 5.0 95.0 9.00 95 5.0 12.00 95 5.0

The settings for the MS probe are typically a cone voltage at 15 V,capillary voltage at 0.8 KV for

Positive mode and 0.4 kV for negative mode. The probe temperature is600° C. and the source temperature is 120° C. The following preparationsillustrate procedures for the preparation of intermediates and methodsfor the preparation of an arylcyclopropyl amino isoquinolinyl amidederivative.

When used in the present application, the following abbreviations havethe meaning set out below:

-   -   AcOH is acetic acid;    -   Bn is benzyl;    -   1,2, DCE is 1,2 dichloroethane    -   DCM is dichloromethane;    -   DCC is N,N′-dicyclohexylcarbodiimide;    -   DME is 1,2-dimethoxyethane;    -   DMF is N,N-dimethylformamide;    -   DMSO is dimethyl sulfoxide;    -   DBU is 1,8-diazabicyclo[5.4.0]undec-7-ene;    -   DMAP is 4-dimethylaminopyridine;    -   EDC/EDAC is N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide        hydrochloride;    -   EtOAc is ethyl acetate;    -   EtOH is ethanol;    -   HOBt is 1-hydroxybenzotriazole;    -   IOP is intraocular pressure    -   MeOH is methanol;    -   rt is room temperature;    -   tBu or t-Bu is tert-butyl;    -   TFA is trifluoroacetic acid;    -   THF is tetrahydrofuran;    -   TLC is thin-layer chromatography and    -   TMSOI is trimethylsulfoxonium iodide

Example 1

Preparation of 4-(2-(methoxycarbonyl)cyclopropyl)benzoic acid (E2). Totrimethylsulfoxonium iodide (TMSOI) in DMSO was added NaH and thesolution was stirred for one hour under N₂.(E)-4-(3-methoxy-3-oxoprop-1-en-1-yl)benzoic acid (E1) dissolved in DMSOwas added and the solution was stirred for 3 hours at room temperature.The mixture was poured into cold EtOAc and HCl (1N) and extracted withEtOAc. The organics were dried (Na₂SO₄), filtered and evaporated. Columnchromatography over silica gel eluting with 0-4% MeOH/CH₂Cl₂ gave pure4-(2-(methoxycarbonyl)cyclopropyl)benzoic acid (E2).

Preparation of trans-methyl2-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylate(E3). To 4-(2-(methoxycarbonyl)cyclopropyl)benzoic acid (E2), in CH₂Cl₂were added EDC, DMAP and pyridin-3-ylmethanamine and the solution wasstirred under N₂ at room temperature for 7 hours. The reaction waspoured into EtOAc/NaHCO₃(sat) and extracted with EtOAc, dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 0-5% MeOH/CH₂Cl₂ gave pure trans-methyl2-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylate(E3).

Preparation oftrans-2-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E4). To trans-methyl2-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylate(E3) in THF/H₂O at 0° C. was added LiOH—H₂O and the solution was warmedto room temperature and stirred for 3 hours. The pH was adjusted to 5with HCl (1N). The aqueous layer was extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated to givetrans-2-(4-((pyridin-3-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E4).

Preparation oftrans-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-3-ylmethyl)benzamide (E8). To trans-2-(4-((pyridin-3-ylmethyl) carbamoyl) phenyl)cyclo-propane-1-carboxylic acid (E4) in pyridine were added EDC, DMAPand 6-aminoisoquinoline and the solution was stirred under N₂ overnight.The mixture was poured into NaHCO₃ and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated. Column chromatography over silica geleluting with 0-3% MeOH/CH₂Cl₂ gave puretrans-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-3-ylmethyl)benzamide(E8).

Using procedures analogous to those set forth above for Scheme 1 andsubstituting the appropriate starting materials, the compounds E8-E39.1,and E39.2-E39.38 were made and E40-E48 (see Table 2) could besynthesized.

TABLE 2

Example R—Z— X₁ X₂ E8

H H E9

H H E10

H H E11

H H E12

H H E13

H H E14

H H E15

H H E15.1

H H E16

H H E17

H H E18

H H E19.1

H H E19.2

H H E20.1

H H E20.2

H H E29.1

H H E29.2

H H E30.1

H H E30.2

H H E31

1-OH H E32

H 7-Br E33

4-F H E34

4-CH₃ H E35

H 5-F E36

1-CH₃ H E37

H H E38

H H E39

H H E39.1

H H Structure: -4-Substituted Cyclopropyl Analogs Example (para) E39.2

E39.3

E39.4

E39.5

E39.6

E39.7

E39.8

E39.9

E39.10

E39.11

E39.12

E39.13

E39.14

E39.15

E39.16

E39.17

E39.18

E39.19

E39.20

E39.21

E39.22

E39.23

E39.24

E39.25

E39.26

E39.27

E39.28

E39.29

E39.30

E39.31

E39.32

E39.33

E39.34

E39.35

E39.36

E39.37

E39.38

Example R—Z— X₁ X₂ E40

3-Cl H E41

H 5-Cl E42

H H E43

H 7-Br E44

1-OH 7-Cl E45

H H E46

4-F H E47

4-Cl H E48

H H.

Example 2

Preparation of trans-methyl2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyacyclopropane-1-carboxylic acid(E49). To trans-2-(4-((pyridin-2-ylmethyl)carbamoyl) phenyl)cyclopropane-1-carboxylate (E3) in THF-H₂O was added LiOH—H₂O and thesolution was stirred at room temperature for 4 hours. The solution wasacidified with HCl (1N) to pH 5 and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated to givetrans-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E49).

Preparation of4-((1R,2R)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E50) and4-((1S,2S)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E51). To trans-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylic acid (E49) in DMF was addedcarbonyldiimidazole and the solution was heated to 40° C. for 2 hoursunder N₂.

Then (1R)-(+)-2,10-camphorsultam chiral auxiliary and DBU were added andthe solution was stirred 5-6 hours at 40° C. After cooling the mixturewas poured into NaHCO₃ (saturated) and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated. Automated column chromatography oversilica gel eluting with 0-20% EtOAc-Hexanes gave a mixture of E50 andE51.

Column Chromatography over silica gel eluting with 40% EtOAc-Hexaneswith 1-2% NEt₃ gave pure4-((1R,2R)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E50) as the faster eluting isomer.4-((1S,2S)-2-((3aR,6S,7aS)-8,8-Dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E51) was obtained from the chromatography as the slower eluting isomerand was further purified by recrystallization from MeOH to give pure4-((1S,2S)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E51).

Preparation of(1R,2R)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E52). To4-((1R,2R)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E50) in THF-H₂O was added LiOH.H₂O and the solution was stirred for 6hours at room temperature. The solution was acidified (HCl, 1N, pHapproximately 2) and extracted with EtOAc to remove(1R)-(+)-2,10-camphorsultam chiral auxiliary. Then, NaHCO₃ (saturated)was added to the aqueous layer until the pH=5. The aqueous layer wasextracted with EtOAc, dried (Na₂SO₄), filtered and evaporated to givepure(1R,2R)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E52).

Preparation of(1S,2S)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E53). To4-((1S,2S)-2-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-3H-3a,6-methanobenzo[c]isothiazole-1-carbonyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E51) in THF-H₂O was added LiOH.H₂O and the solution was stirred for 6hours at room temperature. The solution was acidified (HCl, 1N, pHapproximately 2) and extracted with EtOAc to remove(1R)-(+)-2,10-camphorsultam chiral auxiliary. Then NaHCO₃ (saturated)was added to the aqueous layer until the pH=5. The aqueous layer wasextracted with EtOAc, dried (Na₂SO₄), filtered and evaporated to givepure(1S,2S)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E53).

Preparation of(4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E54). To(1R,2R)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E52) in pyridine was added EDC, DMAP and 6-aminoisoquinoline andthe solution was stirred under N₂ overnight. The mixture was poured intoNaHCO₃ and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 5-8%MeOH—CH₂Cl₂ gave pure(4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E54, 96% R, R)

Preparation of(4-((1S,2S)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E55). To(1S,2S)-2-(4-((pyridin-2-ylmethyl)carbamoyl)phenyl)cyclopropane-1-carboxylicacid (E53) in pyridine was added EDC, DMAP and 6-aminoisoquinoline andthe solution was stirred under N₂ overnight. The mixture was poured intoNaHCO₃ and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 5-8%MeOH—CH₂Cl₂ gave pure (4-((1S,2S)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E55, 97% S,S)

Using procedures analogous to those set forth above for Scheme 2 andsubstituting the appropriate starting materials, the compounds E56-E57.2were made and E58-E91 (see Table 3 and Table 4) could be synthesized

TABLE 3

Ex- ample R—Z— X₁ X₂ E54

H H E56

H H E57.1

H H E57.2

H H E58

1-OH H E59

H H E60

1-Cl H E61

H H E62

H 5-F E63

H H E64

H H E65

4-F H E66

1-OH 4-Cl E67

H H E68

1-OH 7-Cl E69

H H E70

H H E71

H H E72

H H E73

H H E74

H H E75

3-Cl H E76

H 7-Cl E77

H 8-F E78

1-OH 7-Br E79

H H E80

H 7-Br E81

H H E82

1-OH H

TABLE 4

Example R—Z—N(R^(N1)) X₁ X₂ E83

H H E84

1-OH H E85

H H E86

4-Cl H E87

H H E88

4-Cl H E89

H 5-F E90

H H E91

H H

Example 3

Preparation of trans-4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid(E93). To TMSOI in DMSO was added NaH and the solution was stirred forone hour under N₂. (E)-4-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)benzoicacid (E92) dissolved in DMSO was added and the solution was stirred for3 hours at room temperature. The mixture was poured into cold EtOAc andHCl (1 N) and extracted with EtOAc. The organics were dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 5% MeOH—CH₂Cl₂ gave puretrans-4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E93).

Preparation of trans-benzyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E94). Totrans-4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E93) in DMFcooled to 0° C. was added K₂CO₃ and the solution was stirred for 30minutes at 0° C. under N₂. Then, benzyl bromide was added and thesolution was warmed and stirred at room temperature for 2-3 hours. Thereaction was poured into EtOAc/HCl (1N) and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated. Column chromatography over silica geleluting with 0-5% EtOAc-Hexanes gave pure trans-benzyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E94).

Preparation oftrans-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E95). To trans-benzyl 4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate(E94) in CH₂Cl₂ was added TFA and the solution was stirred 3-6 hours atroom temperature. The solvents were evaporated and column chromatography0-5% MeOH—CH₂Cl₂ gave puretrans-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E95).

Preparation of trans-benzyl4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E96). Totrans-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E95) in pyridine was added EDC, DMAP and 6-aminoisoquinoline and thesolution was stirred under N₂ overnight. The mixture was poured intoNaHCO₃ and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 5-8%MeOH—CH₂Cl₂ gave pure trans-benzyl4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E96).

Preparation of trans-pyridin-2-ylmethyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E97). Totrans-4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E93) in CH₂Cl₂was added EDC, DMAP and pyridin-2-ylmethanol and the solution wasstirred under N₂ at room temperature for 7 hours. The reaction waspoured into EtOAc/NaHCO₃ (sat) and extracted with EtOAc, dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 0-60%-70% EtOAc-Hexanes gave pure trans-benzyl pyridin-2-ylmethyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E97).

Preparation oftrans-2-(4-((pyridin-2-ylmethoxy)carbonyl)phenyl)cyclopropane-1-carboxylicacid (E98). To trans-benzyl pyridin-2-ylmethyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E97) in CH₂Cl₂ at 0° C.was added H₂SO₄ and the solution was warmed to room temperature atstirred for 12 hours. The solvents were evaporated and mixture was takenup in NaHCO₃ (saturated) and the pH was adjusted to 5 with HCl (1 N).The aqueous layer was extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated to give trans-pyridin-2-ylmethyl4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E98).

Preparation of trans-pyridin-2-ylmethyl4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl) benzoate (E99). Totrans-2-(4-((pyridin-2-ylmethoxy)carbonyl)phenyl)cyclopropane-1-carboxylicacid (E98) in pyridine was added EDC, DMAP and 6-aminoisoquinoline andthe solution was stirred under N₂ overnight. The mixture was poured intoNaHCO₃ and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 5-8%MeOH—CH₂Cl₂ gave pure pyridin-2-ylmethyl4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl) benzoate (E99).

Using procedures analogous to those set forth above for Schemes 3 and 4and substituting the appropriate starting materials, the compoundsE100-E111 (see Table 5) could be synthesized.

TABLE 5

Example R—Z— X₁ X₂ E96

H H E99

H H E100

1-OH H E100.1

1-OH H E101

1-Cl H E102

H 5-F E103

4-Cl H E104

H 7-Cl E104.1

H 7-Cl E105

H H E106

3-F H E107

1-OH 4-Cl E108

H H E109

1-OH H E110

H H E111

H 5-Cl

Example 4

Preparation of(1S,2S)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E112) and (1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid quinine salt (E113). Totrans-2-(4-((benzyloxy)carbonyl) phenyl)cyclopropane-1-carboxylic acid(E95) in EtOAc was added(R)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol(quinine) and the solution was heated to 80-85° C. The round bottomflask containing the solution was moved to a cork ring and cooled toroom temperature. Crystals were formed over 2 days. The filtrate wasremoved to give(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E113, 44%, 92% RR, 8% SS). The crystals gave(1S,2S)-2-(4-((benzyloxy)carbonyl)phenyl) cyclopropane-1-carboxylic acidquinine salt (E112 59% SS, 41% RR).

Preparation of(1S,2S)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E103). To trans-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid in EtOAc was added(R)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol(quinine) and the solution was heated to 80-85° C. The round bottomflask containing the solution was moved to a cork ring and cooled toroom temperature. Crystals were formed over day. The filtrate wasremoved to give(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E113, 60%, 64% RR, 35% SS) and the crystals left behindwere (1S,2S)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylicacid quinine salt (E112, 84% SS, 16% RR). E112 was recrystallized fromEtOAc two additional times to give(1S,2S)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E112, 98% SS, 2% RR).

Preparation of(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E114).(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acidquinine salt (E113) was dissolved in EtOAc and extracted with HCl (1N).The organics were dried (Na₂SO₄), filtered and evaporated to give(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E114).

Preparation of benzyl4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E115). To(1R,2R)-2-(4-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid(E114) in pyridine was added EDC, DMAP and 6-aminoisoquinoline and thesolution was stirred under N₂ overnight. The mixture was poured intoNaHCO₃ and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 5-8%MeOH—CH₂Cl₂ gave pure benzyl4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E115).

Preparation of4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acid (E116).To 4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E115)in THF-H₂O at 0° C. was added LiOH.H₂O and the solution was stirred atroom temperature for 24 hours. The reaction was acidified to pH 5 withHCl (1N) and the solids were filtered to give4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acid (E116).

Preparation of4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E54). To 4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl) benzoicacid (E116) in CH₂Cl₂ was added EDC, DMAP and 2-picolylamine and thesolution was stirred under N₂ at room temperature overnight. Thereaction was poured into EtOAc/NaHCO₃ (saturated) and extracted withEtOAc, dried (Na₂SO₄), filtered and evaporated. Column chromatographyover silica gel eluting with 5-8% MeOH—CH₂Cl₂ gave pure4-((1R,2R)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E54).

Using procedures analogous to those set forth above for Scheme 6substituting the appropriate starting materials, the compound E69 wasmade and E56, E56.1, E90, and E115.1, and E117-E138 (see Table 6) couldbe synthesized.

TABLE 6

Example R—Z—Y— X₁ X₂ E54

H H E115

H H E115.1

H 5-F E116

H H E69

H H E117

H H E56

H H E56.1

H 5-F E118

1-OH H E119

5-Cl H E120

H 7-F E121

H H E122

H H E123

1-OH 7-Cl E124

H 7-Br E125

H H E126

H H E127

1-OH 4-Cl E128

H H E90

H H E129

H H E130

1-OH H E131

3-Cl H E132

1-F H E133

H H E134

H H E135

5-Cl H E136

4-F H E137

H H E138

H H

Using procedures analogous to those set forth above for Scheme 6.1substituting the appropriate starting materials, E138.1-E138.41 were(see Table 6.1) synthesized.

TABLE 6.1 Example Structure: -R,R and S,S-4-Substutituted Analogs (para)E138.1

E138.2

E138.3

E138.4

E138.5

E138.6

E138.7

E138.8

E138.9

E138.10

E138.11

E138.12

E138.13

E138.14

E138.15

E138.16

E138.17

E138.18

E138.19

E138.20

E138.21

E138.22

E138.23

E138.24

E138.25

E138.26

E138.27

E138.28

E138.29

E138.30

E138.31

E138.32

E138.33

E138.34

E138.35

E138.36

E138.37

E138.38

E138.39

E138.40

Example 5

Preparation of trans-tert-butyl2-(4-(hydroxymethyl)phenyl)cyclopropane-1-carboxylate (E139).

To trans-4-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E93) in THFcooled to 0° C. under N₂ was added BH₃-THF and the solution was warmedto room temperature. After 5 hours the mixture was poured into NaHCO₃(saturated) and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 0-30%EtOAc-Hexanes gave pure of trans-tert-butyl2-((hydroxymethyl)phenyl)cyclopropane-1-carboxylate (E139).

Preparation of trans-tert-butyl2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylate(E140). To trans-tert-butyl2-((hydroxymethyl)phenyl)cyclopropane-1-carboxylate (E139) in CH₂Cl₂ wasadded DMAP and 1-fluoro-3-(isocyanatomethyl)benzene and the solution wasstirred for 24 hours at room temperature under N₂. The mixture waspoured into EtOAc-NH₄Cl, extracted, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 0-30%EtOAc gave trans-tert-butyl 2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylate (E140).

Preparation oftrans-2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylicacid (E141). To trans-tert-butyl2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylate(E140) in CH₂Cl₂ was added TFA and the solution was stirred at roomtemperature overnight. The solvents were evaporated and columnchromatography over silica gel eluting with 20% EtOAc-Hexanes, 2% AcOHgave puretrans-2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylicacid (E141).

Preparation of trans-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzyl(3-fluorobenzyl)carbamate (E142). Totrans-2-(4-((((3-fluorobenzyl)carbamoyl)oxy)methyl)phenyl)cyclopropane-1-carboxylic acid (E141) in pyridine wereadded EDC, DMAP and 6-aminoisoquinoline and the solution was stirredunder N₂, overnight at room temperature. The reaction mixture was pouredinto NaHCO₃ (saturated) and extracted with EtOAc, dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 4% MeOH—CH₂Cl₂ gave pure trans-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzyl (3-fluorobenzyl)carbamate (E142).

Using procedures analogous to those set forth for Scheme 7 andsubstituting the appropriate starting materials, the compound E143 wasmade and E144-E153 (see Table 7) could be synthesized.

TABLE 7

Example R—Z— X₁ X₂ E142

H H E143

H H E144

H H E145

H H E146

1-OH H E147

H 5-Cl E148

H 7-F E149

H H E150

1-OH H E151

1-OH 7-Cl E152

H 7-Br E153

H H

Using procedures analogous to those set forth for Scheme 7 andsubstituting the appropriate starting materials, the compoundE153.1-E153.4 were made (Table 7.1)

TABLE 7.1 Structure: -4-Substutituted Cyclopropyl Analogs Example (para)E153.1

E153.2

E153.3

E153.4

Example 6

Preparation of(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylacrylamide(E155). To(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)acrylic acid(E154) in anhydrous dichloromethane was added EDC, DMAP andN,O-dimethylhydroxylamine and the solution was stirred at roomtemperature for 4 hours. The reaction was diluted with dichloromethaneand washed with deionized H₂O, dried over Na₂SO₄, filtered andconcentrated. Column chromatography over silica gel eluting with 0 to 2%MeOH/CH₂Cl₂ gave pure(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylacrylamide(E155).

Preparation oftrans2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylcyclopropane-1-carboxamide(E156). To TMSOI in DMSO was added NaH and the solution was stirred forone hour under N₂.(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylacrylamide(E155) dissolved in DMSO was added dropwise and the solution was stirredfor 3 hours at room temperature. The mixture was poured over deionizedH₂O and extracted with EtOAc. The organics were dried (Na₂SO₄), filteredand concentrated. Column chromatography over silica gel eluting with0-5% MeOH/CH₂Cl₂ gave puretrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylcyclopropane-1-carboxamide(E156).

Preparation oftrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)cyclopropane-1-carboxylic acid (E157). To a suspension oftrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-methoxy-N-methylcyclopropane-1-carboxamide(E156) in diethyl ether and deionized water was added potassiumt-butoxide and stirred at room temperature 16 hours. The pH was adjustedto 5 with HCl (1N) and the aqueous layer was extracted with EtOAc, dried(Na₂SO₄), filtered and concentrated to givetrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)cyclopropane-1-carboxylicacid (E157).

Preparation oftrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E158). Totrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)cyclopropane-1-carboxylicacid (E157) in anhydrous pyridine were added EDC, DMAP and6-aminoisoquinoline and the solution was stirred under N₂ overnight. Thereaction mixture was concentrated. Column chromatography over silica geleluting with 0-5% MeOH/CH₂Cl₂ gave puretrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E158).

Preparation oftrans-2-(4-formylphenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E159). To a suspension oftrans-2-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E158) in deionized H₂O was added AcOH and the solution was heated to65° C. for 3 hours. The reaction was quenched with NaHCO₃ (saturated)and extracted with EtOAc, dried (Na₂SO₄), filtered and concentrated.Column chromatography over silica gel eluting with 0-5% MeOH—CH₂Cl₂ gavepuretrans-2-(4-formylphenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E159).

Preparation oftrans-N-(isoquinolin-6-yl)-2-(4-(((pyridin-3-ylmethyl)amino)methyl)phenyl)cyclopropane-1-carboxamide(E160). Totrans-2-(4-formylphenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E159) in anhydrous 1,2-dichloroethane was added pyridin-3-ylmethanamineand the solution was stirred at room temperature under N₂ for 30 minutesbefore adding sodium triacetoxyborohydride and stirring overnight. Thereaction was poured into EtOAc/NaHCO₃ (saturated) and extracted withEtOAc, dried (Na₂SO₄), filtered and evaporated. Column chromatographyover silica gel eluting with 0-5% MeOH/CH₂Cl₂ gave puretrans-N-(isoquinolin-6-yl)-2-(4-(((pyridin-3-ylmethyl)amino)methyl)phenyl)cyclopropane-1-carboxamide(E160).

Using the procedures analogous to those set forth for Scheme 8 andsubstituting the appropriate starting materials, the compoundsE161-E162.2 were made and E163-E165 (see Table 8) could be synthesized.

TABLE 8

Example R—Z— X₁ X₂ E160

H H E161

H H E-162.1

H H E162.2

H H E163

H H E164

H H E165

H H

Example 7

Preparation of (E)-3-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)benzoic acid(E166). To 3-formyl benzoic acid and tert-butyldiethyl phosphonoacetatein 1,2-dimethoxyethane cooled to 0° C. was added NaH and the solutionwas stirred for 1 hour at 0° C. and 2.5 hours at room temperature underN₂. The solution was quenched with HCl (1 N) and extracted with EtOAc,dried (Na₂SO₄), filtered and evaporated. Column chromatography oversilica gel eluting with 15% EtOAc-Hexanes gave pure(E)-3-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)benzoic acid (E166).

Preparation of trans-3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid(E167). To TMSOI in DMSO was added NaH and the mixture was stirred atroom temperature under N₂ for one hour. Then,(E)-3-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)benzoic acid (E166) in DMSOwas added and the solution stirred for 3 hours at room temperature. Thesolution was poured into HCl (1N) and EtOAc and extracted with EtOAc,dried (Na₂SO₄), filtered and evaporated. Column chromatography oversilica gel eluting with 0-5% MeOH—CH₂Cl₂ gave puretrans-3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E167).

Preparation of trans-benzyl3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E168). Totrans-3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoic acid (E167) in DMFat 0° C. was added K₂CO₃ and the solution stirred for 40 minutes underN₂. Then, benzyl bromide was added and the mixture was warmed to roomtemperature and stirred for 1 hour. The mixture was poured into HCl(1N)-EtOAc and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 0-5%EtOAc-Hexanes gave pure trans-benzyl3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E168).

Preparation of trans-benzyl2-(3-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid (E169).To trans-benzyl 3-(2-(tert-butoxycarbonyl)cyclopropyl)benzoate (E168) inCH₂Cl₂ at 0° C. was added TFA and the solution was warmed to roomtemperature and stirred for 1.5 hours. The solvents were evaporated andcolumn chromatography over silica gel eluting with 5%-MeOH—CH₂Cl₂ gavepure trans-benzyl2-(3-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid (E169).

Preparation of trans-benzyl 3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E170). To trans-benzyl2-(3-((benzyloxy)carbonyl)phenyl)cyclopropane-1-carboxylic acid (E169)in pyridine were added EDC, DMAP and 6-aminoisoquinoline and thesolution was stirred overnight at room temperature under N₂. Thesolution was poured into NaHCO₃ and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated. Column chromatography over silica geleluting with 0-4% MeOH—CH₂Cl₂ gave pure trans-benzyl3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E170).

Preparation of trans-benzyl3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acid (E171). Totrans-benzyl 3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E170)in THF and H₂O was added LiOH.H₂O and the solution was stirred at roomtemperature for 2.5 hours. HCl (1N) was added until the pH=5 and thenEtOAc was added to precipitate. The solids were filtered, washed withwater and Et₂O and dried to give trans-benzyl3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl) benzoic acid (E171).

Preparation oftrans-3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethypenzamide(E172). To trans-benzyl 3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acid (E171) in pyridine were added EDC, DMAP and 2-picolylamineand the solution was stirred at room temperature overnight under N₂.Then the solution was poured into NaHCO₃ (saturated) and extracted withEtOAc, dried (Na₂SO₄), filtered and evaporated. Column chromatographyover silica gel eluting with 5-9% MeOH—CH₂Cl₂ gave puretrans-3-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(pyridin-2-ylmethyl)benzamide(E172).

Using procedures analogous to those set forth for Scheme 9 andsubstituting the appropriate starting materials, the compounds E173-E175were made and E176-E186 (see Table 9) could be synthesized.

TABLE 9

Ex- am- ple R—Z— Y X₁ X₂ E170

—OC(O)— H H E172

—NHC(O)— H H E173

—NHC(O)— H H E174

—NHC(O)— H H E175

—NHC(O)— H H E176

—OC(O)— 5-F H E177

—OC(O)— H H E178

—OC(O)— 4-Cl H E179

—NHC(O)— H H E180

—NHC(O)— H H E181

—NHC(O)— 1-OH 5- Cl E182

—NHC(O)— H H E183

—NHC(O)— 4-Cl H E184

—NHC(O)— 4-F H E185

—NHC(O)— 3-Me H E186

—NHC(O)— H H

Using procedures analogous to those set forth for Scheme 9 andsubstituting the appropriate starting materials, the compoundsE186.1-E186.36 were also made. (see Table 9.1)

TABLE 9.1 Structure: -3-Substutituted Cyclopropyl Analogs Example (meta)E186.1

E186.2

E186.3

E186.4

E186.5

E186.6

E186.7

E186.8

E186.9

E186.10

E186.11

E186.12

E186.13

E186.14

E186.15

E186.16

E186.17

E186.18

E186.19

E186.20

E186.21

E186.22

E186.23

E186.24

E186.25

E186.26

E186.27

E186.28

E186.29

E186.30

E186.31

E186.32

E186.33

E186.34

E186.35

E186.36

Using procedures analogous to those set forth for Scheme 6.1 andsubstituting the appropriate starting materials (E-166), the compoundsE186.37-E186.44 were made. (See Table 9.2)

TABLE 9.2 Structure: -R,R and S,S -3-Substutituted Example CyclopropylAnalogs (meta) E186.37

E186.38

E186.39

E186.40

E186.41

E186.42

E186.43

E186.44

Example 8

Preparation of tert-butyl(E)-3-fluoro-4-(3-(methoxy(methyl)amino)-3-oxoprop-1-en-1-yl)benzoate(E188). To (E)-3-(4-(tert-butoxycarbonyl)-2-fluorophenyl)acrylic acid(E187) in CH₂Cl₂ were added EDC, DMAP and N,O-dimethylhydroxylamine andthe solution was stirred at room temperature for 6.5 hours. Then themixture was poured into a cold (0° C.) solution of HCl (1N) and EtOAcand further extracted with EtOAc. The organics were extracted with NaCl(saturated), dried (Na₂SO₄) filtered and evaporated. Columnchromatography over silica gel eluting with 0-50% EtOAc-Hexanes gavetert-butyl(E)-3-fluoro-4-(3-(methoxy(methyl)amino)-3-oxoprop-1-en-1-yl)benzoate(E188).

Preparation of trans-tert-butyl3-fluoro-4-(2-(methoxy(methyl)carbamoyl)cyclopropyl)benzoate (E189). ToTMSOI in DMSO was added NaH and the mixture was stirred at roomtemperature for one hour. Then, tert-butyl(E)-3-fluoro-4-(3-(methoxy(methyl)amino)-3-oxoprop-1-en-1-yl)benzoate(E188) in DMSO was added and the solution stirred for 3.5 hours at roomtemperature. The solution was poured into HCl (1N) and EtOAc (cooled to0° C.) and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 0-50%EtOAc-Hexanes gave pure trans-tert-butyl3-fluoro-4-(2-(methoxy(methyl)carbamoyl)cyclopropyl)benzoate (E189).

Preparation oftrans-2-(4-(tert-butoxycarbonyl)-2-fluorophenyl)cyclopropane-1-carboxylicacid (E190). To tert-butyl3-fluoro-4-(2-(methoxy(methyl)carbamoyl)cyclopropyl)benzoate (E189) inEtOH was added a solution of KOH in water and the solution was stirredfor 24 hours. The solution was poured into HCl (1 N) and EtOAc andfurther extracted with EtOAc, dried (Na₂SO₄), filtered and evaporated.Column chromatography over silica gel eluting with 5% MeOH—CH₂Cl₂ gavepuretrans-2-(4-(tert-butoxycarbonyl)-2-fluorophenyl)cyclopropane-1-carboxylicacid (E190).

Preparation of trans-tert-butyl3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E191). Totrans-2-(4-(tert-butoxycarbonyl)-2-fluorophenyl)cyclopropane-1-carboxylicacid (E190) in pyridine were added EDC, DMAP and 6-aminoisoquinoline andthe solution was stirred at room temperature overnight. The solution waspoured into NaHCO₃ (saturated) and extracted with EtOAc, dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 4% MeOH—CH₂Cl₂ gave trans-tert-butyl3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E191).

Preparation oftrans-3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acidhydrochloride (E192). To trans-tert-butyl3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoate (E191) inCH₂Cl₂ was added HCl (4 N in dioxane) and the reaction was allowed tostir overnight. The solvents were evaporated and the compound was driedon the high vacuum to givetrans-3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acidhydrochloride (E192).

Preparation oftrans-3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(4-methoxybenzyl)benzamide(E193). Totrans-3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)benzoic acidhydrochloride (E192) in pyridine were added EDC, DMAP and4-methoxybenzylamine and the solution was stirred overnight at roomtemperature. The reaction was poured into NaHCO₃ (saturated) andextracted with EtOAc, dried (Na₂SO₄), filtered and evaporated. Columnchromatography over silica gel eluting with 5% MeOH—CH₂Cl₂ gave puretrans-3-fluoro-4-(2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)-N-(4-methoxybenzyl)benzamide(E193).

Using procedures analogous to those set forth for Scheme 10 andsubstituting the appropriate starting materials, the compoundsE194-E195.2 were made and E191.1 and E196-E206 (see Table 10) could besynthesized.

TABLE 10

Example R—Z— Y X₁ X₂ X₃ E193

—NHC(O)— H H 3-F E194

—NHC(O)— H H 3-F E195

—NHC(O)— H H 3-F E195.1

—NHC(O)— H H 2-F E195.2

—NHC(O)— H H 2-F E196

—OC(O)— H H 3-F E197

—OC(O)— 1-OH 4-Cl 2-Cl E198

—OC(O)— 4-Cl H 2-F E199

—NHC(O)— H 5-F 3-Cl E200

—NHC(O)— H H 2-F E201

—NHC(O)— H H 3-F E202

—NHC(O)— 1-OH 5-Cl 2-OMe E203

—NHC(O)— H H 2-F E204

—NHC(O)— H H 2-F E205

—NHC(O)— H 5-Cl 2-CF3 E206

—NHC(O)— H H 3-OMe E191.1

—OC(O)— H H H

Example 9

Preparation of methyl (E)-3-(4-(benzyloxy)phenyl)acrylate (E207). Tomethyl (E)-3-(4-hydroxyphenyl)acrylate in DMF at 0° C. was added K₂CO₃and the solution stirred at 0° C. for 30 minutes. Then benzyl bromidewas added and the reaction was warmed to room temperature and stirredovernight under N₂. The mixture was poured into HCl (1N) and EtOAc andextracted with EtOAc, dried (Na₂SO₄), filtered and evaporated. Columnchromatography over silica gel eluting with 0-70% EtOAc-Hexanes gavepure (E)-3-(4-(benzyloxy)phenyl)acrylate (E207).

Preparation oftrans-methyl-2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylate (E208).To TMSOI in DMSO was added NaH and the solution was stirred for 1 hour.Then a solution of (E)-3-(4-(benzyloxy)phenyl)acrylate (E207) in DMSOwas added and the reaction stirred for an additional 3 hours, pouredinto HCl (1N) and EtOAc and extracted with EtOAc, dried (Na₂SO₄),filtered and evaporated. Column chromatography over silica gel elutingwith 0-10% EtOAc-Hexanes gave pure trans-methyl-2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylate (E208).

Preparation of trans-2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylicacid (E209). Totrans-methyl-2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylate (E208) inTHF and water was added LiOH.H₂O and the reaction was stirred at roomtemperature for 4 days. The mixture was poured into HCl (1 N) and EtOAcand extracted with EtOAc, dried (Na₂SO₄), filtered and evaporated.Column chromatography over silica gel eluting with 20% EtOAc-Hexanes0.2% AcOH gave puretrans-2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylic acid (E209).

Preparation oftrans-2-(4-(benzyloxy)phenyl)-N-(isoquinolin-6-Acyclopropane-1-carboxamide(E210). To 2-(4-(benzyloxy)phenyl)cyclopropane-1-carboxylic acid (E209)in pyridine were added EDC, DMAP and 6-aminoisoquinoline and thesolution was stirred at room temperature under N₂ overnight. Thereaction mixture was poured into NaHCO₃ (saturated) and extracted withEtOAc, dried (Na₂SO₄), filtered and evaporated to givetrans-2-(4-(benzyloxy)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E210).

Using procedures analogous to those set forth for Scheme 11 andsubstituting the appropriate starting materials, the compounds E211-E221(see Table 11) could be synthesized.

TABLE 11

Example R—Z X₁ X₂ X₃ E210

H H H E211

H H H E212

H 5-F H E213

4-Cl H 3-F E214

H H 2-F E215

1-OH H H E216

H 5-Cl 3-F E217

3-Cl H H E218

H 7-Cl H E219

H H H E220

H H H E221

H 5-F 3-F

Using procedures analogous to those set forth for Scheme 11 andsubstituting the appropriate starting materials, the compoundsE221.1-E221.3 (see Table 11,11 were made.

TABLE 11.1 Example E221.1

E221.2

E221.3

Example 10

Preparation of(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)acrylamide(E222). To(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)acrylic acid(E154) in anhydrous pyridine were added EDC, DMAP and6-aminoisoquinoline and the solution was stirred under N₂ overnight. Thereaction mixture was concentrated. Column chromatography over silica geleluting with 0-5% MeOH/CH₂Cl₂ gave pure(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)acrylamide(E222).

Preparation of4-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-1-(isoquinolin-6-yl)pyrrolidin-2-one(E223). To TMSOI in DMSO was added NaH and solution was stirred for onehour under N₂.(E)-3-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-N-(isoquinolin-6-yl)acrylamide(E222) dissolved in DMSO was added dropwise and the solution was stirredfor 3 hours at room temperature. The mixture was poured over deionizedH₂O and extracted with EtOAc. The organics were dried (Na₂SO₄), filteredand concentrated. Column chromatography over silica gel eluting with0-5% MeOH/CH₂Cl₂ gave pure4-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-1-(isoquinolin-6-yl)pyrrolidin-2-one(E223).

Preparation of 4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzaldehyde(E224). To a suspension of4-(4-((4S,5S)-4,5-dimethyl-1,3-dioxolan-2-yl)phenyl)-1-(isoquinolin-6-yl)pyrrolidin-2-one(E223) in deionized water was added AcOH and stirred at 65° C. for 3hours. The reaction was poured into EtOAc/NaHCO₃ (saturated) andextracted with EtOAc, dried (Na₂SO₄), filtered and evaporated. Columnchromatography over silica gel eluting with 0-5% MeOH/CH₂Cl₂ gave pure4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzaldehyde (E224).

Preparation of1-(isoquinolin-6-yl)-4-(4-(((pyridin-3-ylmethyl)amino)methyl)phenyl)pyrrolidin-2-one (E225). To4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benz-aldehyde (E224) inanhydrous 1,2-dichloroethane was added pyridin-3-ylmethanamine and thesolution was stirred at room temperature under N₂ for 30 minutes beforeadding sodium triacetoxyborohydride and stirring overnight. The reactionwas poured into EtOAc/NaHCO₃ (saturated) and extracted with EtOAc, dried(Na₂SO₄), filtered and evaporated. Column chromatography over silica geleluting with 0-5% MeOH/CH₂Cl₂ gave pure1-(isoquinolin-6-yl)-4-(4-(((pyridin-3-ylmethyl)amino)methyl)phenyl)pyrrolidin-2-one(E225).

Using procedures analogous to those set forth for Scheme 12 andsubstituting the appropriate starting materials, the compounds E226-E228(see Table 12) were made.

TABLE 12

Example R—Z— X₁ X₂ X₃ E225

H H H E226

H H H E227

H H H E228

H H H

Example 11

Preparation of tert-butyl(E)-4-(3-(isoquinolin-6-ylamino)-3-oxoprop-1-en-1-yl)benzoate (E229). To(E)-3-(4-(tert-butoxycarbonyl)phenyl)acrylic acid in anhydrous pyridinewere added EDC, DMAP and 6-aminoisoquinoline and the solution wasstirred under N₂ overnight. The reaction mixture was concentrated.Column chromatography over silica gel eluting with 0-4% MeOH/CH₂Cl₂ gavepure tert-butyl(E)-4-(3-(isoquinolin-6-ylamino)-3-oxoprop-1-en-1-yl)benzoate (E229).

Preparation of tert-butyl4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoate (E230). To TMSOIin DMSO was added NaH and solution was stirred for one hour under N₂.tert-Butyl (E)-4-(3-(isoquinolin-6-ylamino)-3-oxoprop-1-en-1-yl)benzoate(E229) dissolved in DMSO was added dropwise and the solution was stirredfor 3 hours at room temperature. The mixture was poured over deionizedH₂O and extracted with EtOAc. The organigs were dried (Na₂SO₄), filteredand concentrated. Column chromatography over silica gel eluting with0-5% MeOH/CH₂Cl₂ gave pure tert-butyl4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoate (E230).

Preparation of 4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoic acid(E231). To tert-butyl4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoate (E230) indichloromethane was added 4M HCl in dioxane and stirred at roomtemperature for 3 hours. The reaction mixture was concentrated to givepure 4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoic acid (E231).

Preparation of4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)-N-(pyridin-3-ylmethyl)benzamide(E232). To 4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)benzoic acid(E231) in anhydrous CH₂Cl₂ were added EDC, DMAP andpyridin-3-ylmethanamine and the solution was stirred under N₂ at roomtemperature for 7 hours. The reaction was poured into EtOAc/NaHCO₃(saturated) and extracted with EtOAc, dried (Na₂SO₄), filtered andevaporated. Column chromatography over silica gel eluting with 0-5%MeOH/CH₂Cl₂ gave pure4-(1-(isoquinolin-6-yl)-5-oxopyrrolidin-3-yl)-N-(pyridin-3-ylmethyl)benzamide(E232).

Using procedures analogous to those set forth for Scheme 13 andsubstituting the appropriate starting materials, the compoundsE233-E234.2 were made and E235-E243 (see Table 13) could be synthesized.

TABLE 13

Example R—Z— X₁ X₂ X₃ E232

H H H E233

H H H   E234.1

H H H   E234.2

H H H E235

H H H E236

H H 3-F E237

1-OH 5-F H E238

H H 3-Me E239

4-Cl H H E240

5-F H 2-Cl E241

H H H E242

5-F H 2-F E243

H H 3-F

Using procedures analogous to those set forth for Scheme 13 andsubstituting the appropriate starting materials, the compoundsE243.1-E243.3 were made (see Table 13.1)

TABLE 13.1 Example Pyrrolidinone Analogs E243.1

E243.2

E243.3

Example 12

Below are the typical procedures used for the synthesis of the productsfrom the above scheme 14.

Methyl (trans)-2-phenylcyclopropane-1-carboxylate. A solution ofcommercially-available trans-2-phenylcyclopropane-1-carboxylic acid (204mg, 1.26 mmol) in 3 mL ethyl acetate (EtOAc) and 0.2 mL MeOH was treatedwith Me₃SiCHN₂ (0.69 mL of 2.0 M solution in heptane, 1.38 mmol) overabout 1 minute dropwise and the resulting yellow solution was stirred 1hour at room temperature. TLC (Hexanes-EtOAc-HOAc, 80:20:1) showed thecompletion of the reaction. The reaction mixture was concentrated on arotovap (220 mg of the crude material) and purified using columnchromatography on silica gel (Hexane-EtOAc, 95:5-80-20). Methyltrans)-2-phenylcyclopropane-1-carboxylate (178 mg) was isolated as anoil. ES-API calc'd for C₁₁H₁₂O₂ 176.08, [M+H]⁺ found 177.1

Ethyl-(trans)-2-(4-(chlorosulfonyl)phenyl) cyclopropane-1-carboxylate(E244.1) Chlorosulfonic acid (15 mL) in dry 50 mL round-bottomed flaskwas cooled with an ice bath and treated portion-wise with ethylrel-(1R,2R)-2-phenylcyclopropane-1-carboxylate (3.15 g, 15.56 mmol)during 30 minutes under N₂ and stirring. Then the cooling bath wasremoved and the reaction mixture (pale brown solution) was stirred 3hours at room temperature. TLC (Hexane-EtOAc 60:40) showed thecompletion of the reaction. The reaction mixture was slowly andcarefully poured into a 500 mL Erlenmeyer flask with 100 g of ice,stirred 5 minutes and then extracted with EtOAc (200 mL, 2×100 mL). Thecombined organic layers were washed with water-brine (1:1, 2×50 mL),dried over Na₂SO₄ and concentrated. The crude product (5.2 g) waspurified using column chromatography on silica gel (Hexane-EtOAc,99:1-90-10). Chlorosulfonate E244.1 (3 g) was isolated as an oil. ES-APIcalcd for C₁₂H₁₃ClO₄S 288.02 [M+H]⁺; found 289.0.

trans-Methyl 2-(4-(chlorosulfonyl)phenyl)cyclopropane-1-carboxylate(E244.2). The title compound was prepared from methyltrans-2-phenylcyclopropane-1-carboxylate using the procedure of E244.1.E244.2: ES-API calc'd for C₁₁H₁₁ClO₄S 274.01, [M+NH_(a)]⁺ found 293.0trans-methyl 2-(4-(N-benzylsulfamoyl)phenyl)cyclopropane-1-carboxylate(E245A). Sulfonyl chloride E244.2 (110 mg, 0.4 mmol) in dry pyridine (2mL) in a dried 10 mL round-bottomed flask was cooled with an ice bathand treated with aniline (0.04 mL, 0.44 mmol) in one portion under N₂and stirring. Then the cooling bath was removed and the reaction mixture(deep orange slurry) was stirred for 1 hour at room temperature. TLC(Hexane-EtOAc 60:40) showed the completion of the reaction; no startingmaterial remained and a more polar product was formed. The reactionmixture was concentrated, diluted with EtOAc (50 mL), washed withwater-brine (1:1, 2×5 mL), brine (5 mL), dried over Na₂SO₄ andconcentrated. The crude product (104 mg) was purified using columnchromatography on silica gel (Hexane-EtOAc, 90:10-75:25). E245A (90 mg)was isolated as an oil. ES-API calc'd for C₁₇H₁₇NO₄S 331.09, [M+H]⁺found 332.0

Using similar procedures, the following compounds were synthesized:

trans-ethyl2-(4-(N-(pyridin-3-ylmethyl)sulfamoyl)phenyl)cyclopropane-1-carboxylate(E245B): ES-API calc'd for C₁₈H₂OS 360.11, [M+H]⁺ found 361.0trans-Ethyl2-(4-(N-(3-(dimethylamino)propyl)sulfamoyl)phenyl)cyclopropane-1-carboxylate(E245C): ES-API calc'd for C₁₇H₂₆N₂O₄S 354.16, [M+H] found 355.1

trans-tert-butyl4-((4-(2-(ethoxycarbonyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylate(E245D): ES-API calc'd for C₂₃H₃₄N₂O₆S 466.21, [M+Na]⁺ found 489.1

trans-tert-butyl(3S)-3-(((4-(2-(ethoxycarbonyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylateE245E): ES-API calc'd for C₂₃H₃₄N₂O₆S 466.21, [M−H]⁺ found 465.2

trans-tert-butyl(3R)-3-(((4-(2-(ethoxycarbonyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylateE245F): ES-API calc'd for C₂₃H₃₄N₂O₆S 466.21, [M−H]⁺ found 465.2

trans-tert-butyl4-((4-(2-(ethoxycarbonyl)cyclopropyl)phenyl)sulfonamido)piperidine-1-carboxylate(E245G): ES-API calc'd for C₂₂H₃₂N₂O₆S 452.20, [M+Na]⁺ found 475.1

trans-tert-butyl4-(4-(2-(ethoxycarbonyl)cyclopropyl)phenyl)sulfonyl)piperazine-1-carboxylate(E245H): ES-API calc'd for C₂₁H₃₀N₂O₆S 438.18, [M+Na]⁺ found461.1—Preparation of the Isoquinolyl amides from their respectiveesters:

(trans)-2-(4-(N-phenylsulfamoyl)phenyl)cyclopropane-1-carboxylic acid(E246A): A solution of ester E245A in ethanol was treated with 1N LiOHand left to stir overnight at room temperature. The next day TLC(Hexane-EtOAc-HOAc, 60:40:1) showed the completion of the reaction. Thereaction mixture was acidified till pH 3 using KHSO₄, extracted withEtOAc (50 mL, 2×20 mL), the organic layers were washed with brine (5mL), dried over Na₂SO₄ and concentrated. The crude product (77 mg) waspurified using column chromatography on silica gel (Hexane-EtOAc-HOAc,90:10:0.1-70:30:0.1). E246A (67 mg) was isolated as an oil. ES-APIcalc'd for C₁₅H₁₅NO₄S 317.07, [M+H]⁺ found 318.0

Using similar procedures, the following compounds were synthesized:

trans-2-(4-(N-(pyridin-3-ylmethyl)sulfamoyl)phenyl)cyclopropane-1-carboxylicacid (E246B): Crude material carried on to next step. No ¹H NMR becauseused in next reaction without purification; ES-API calc'd forC₁₆H₁₆N₂O₄S 332.08, [M+H]⁺ found 333.0

trans-2-(4-(N-(3-(dimethylamino) propyl)sulfamoyl)phenyl)cyclopropane-1-carboxylic acid (E246C): Crude material carried on tonext step without purification; ES-API calc'd for C₁₅H₂₂N₂O₄S 326.13,[M+H]⁺ found 327.1

trans-2-(4-(N-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)sulfamoyl)phenyl)cyclopropane-1-carboxylic acid (E246D): Crude material carried onto next step. No ¹H NMR because used in next reaction withoutpurification; ES-API calc'd for C₂₁H₃₀N₂O₆S 438.18, [M+Na]⁺ found 461.1

trans-2-(4-(N—(((S)-1-(tert-butoxycarbonyl) piperidin-3-yl)methyl)sulfamoyl) phenyl) cyclopropane-1-carboxylic acid (E246E): Crudematerial carried on to next step. No ¹H NMR was taken because it wasused in next reaction without purification: ES-API calc'd forC₂₁H₃₀N₂O₆S 438.18, [M+Na]⁺ found 461.1

trans-2-(4-(N—(((R)-1-(tert-butoxycarbonyl)piperidin-3-yl)methyl)sulfamoyl)phenyl)cyclopropane-1-carboxylic acid (E246F): ES-API calcd forC₂₁H₃₀N₂O₆S 438.18, [M+Na]⁺ found 461.1

trans-2-(4-(N-(1-(tert-butoxycarbonyl)piperidin-4-yOsulfamoyl)phenyl)cyclopropane-1-carboxylic acid (E246G): ES-API calc'd for C₂₀H₂₈N₂O₆S424.17, [M+Na]⁺ found 447.1

trans-2-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)phenyl)cyclopropane-1-carboxylic acid (E246H): No ¹H NMR; used in next reactionwithout purification; ES-API calc'd for C₁₉H₂₆N₂O₆S 410.15, [M+Na]⁺found 433.1trans-N-(isoquinolin-6-yl)-2-(4-(N-phenylsulfamoyl)phenyl)cyclopropane-1-carboxamide(E247A): A solution of acid E246A (65 mg, 0.2 mmol) in DMF (2 mL) in adried 10 mL round-bottomed flask was treated with HOBt (36.5 mg, 0.27mmol), 6-aminoisoquinoline (28.8 mg, 0.2 mmol), and N-methylmorpholine(0.029 mL, 0.27 mmol), cooled with an ice bath and then EDC HCl (42 mg,0.22 mmol) was added in one portion under N₂ and stirring. Then thecooling bath was removed and the reaction mixture was left to stir 3days at room temperature. After that TLC (DCM-MeOH—HOAc, 93:7:1) showedthe completion of the reaction. The reaction mixture was diluted withwater (5 mL), extracted with EtOAc (50 mL, 2×20 mL), the organic layerswere washed with brine (5 mL), dried over Na₂SO₄ and concentrated. Thecrude product (75 mg) was purified using column chromatography on silicagel (DCM-MeOH, 99:1-95:5). E247A (25 mg) was isolated as an oil. ES-APIcalc'd for C₂₅H₂₁N₃₀₃S 443.13, [M+H]⁺ found 444.1

Using similar procedures, the following compounds were synthesized:

trans-N-(isoquinolin-6-yl)-2-(4-(N-(pyridin-3-ylmethyl)sulfamoyl)phenyl)cyclo-propane-1-carboxamide(E247B): ES-API calc'd for C₂₅H₂₂N₄O₃S 458.14, [M+H]⁺ found 459.1

trans-2-(4-(N-(3-(dimethylamino)propyl)sulfamoyl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide (E247C)

tert-butyl4-(((4-((trans)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylate(E247D): ES-API calc'd for C₃₀H₃₆N₄O₅S 564.24, [M+H]⁺ found 565.2

tert-butyl(S)-3-(((4-((trans)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylate(E247E): ES-API calc'd for C₃₀H₃₆N₄O₅S 564.24, [M+H]⁺ found 565.2

tert-butyl(R)-3-(((4-((trans)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)phenyl)sulfonamido)methyl)piperidine-1-carboxylate(E247F): ES-API calc'd for C₃₀H₃₆N₄O₅S: 564.24, [M+H]⁺, found 565.24

tert-butyl4-((4-((trans)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)phenyl)sulfonamido)piperidine-1-carboxylate(E247G): ES-API calc'd for C₂₉H₃₄N₄O₅S 550.22, [M+H]⁺ found 551.2

tert-butyl4-((4-((trans)-2-(isoquinolin-6-ylcarbamoyl)cyclopropyl)phenyl)sulfonyl)piperazine-1-carboxylate(E247H): ES-API calc'd for C₂₈H₃₂N₄O₅S 536.21, [M+H]⁺ found 537.2

Example 13

trans-N-(isoquinolin-6-yl)-2-(4-(N—(((R)-piperidin-3-yl)methyl)sulfamoyl)phenyl)-cyclopropane-1-carboxamidedihydrochloride (E248F HCl): A solution of Boc-protected amine E247F (17mg, 0.03 mmol) in 2 mL isopropyl alcohol (IPA) was treated with 4N HClin dioxane (0.075 mL, 0.3 mmol) under N₂ and left to stir overnight atroom temperature. TLC (CH₂Cl₂-MeOH—HOAc, 90:10:1) showed disappearanceof the starting material and the formation of the product. Reactionmixture was concentrated with ether (3×5 mL) and dried in high vacuumproviding pure product E248F.HCl (17 mg).

trans-N-(isoquinolin-6-yl)-2-(4-(N-(piperidin-4-ylmethyl)sulfamoyl)phenyl)cyclopropane-1-carboxamide dihydrochloride (E248D HCl): ES-API calc'dfor C₂₅H₂₈N₄O₃S (free base) 464.19, [M+H]⁺ found 465.1

trans-N-(isoquinolin-6-yl)-2-(4-(N—(((S)-piperidin-3-yl)methyl)sulfamoyl)phenyl)cyclopropane-1-carboxamide dihydrochloride (E248E HCl) ES-APIcalc'd for C₂₅H₂₈N₄O₃S (free base) 464.19, [M+H]⁺ found 465.1

trans-N-(isoquinolin-6-yl)-2-(4-(N-(piperidin-4-yOsulfamoyl)phenyl)cyclo-propane-1-carboxamidedihydrochloride (E248G HCl):

trans)-N-(isoquinolin-6-yl)-2-(4-(piperazin-1-ylsulfonyl)phenyl)cyclopropane-1-carboxamidedihydrochloride (E248H HCl): ES-API calc'd for C₂₃H₂₄N₄O₃S (free base)436.16, [M+H]⁺ found 437.1

Using analogous or modified procedure to those set forth for Scheme14-15 or and substituting the appropriate starting materials, thecompounds E247A, E247B, E248D-H and E249.1-249.10 were made (see Table13.1)

TABLE 13.1 Examples E247A

E247B

E248D

E248E

E248H

E248F

E248G

E249.1

E249.2

E249.4

E249.5

E249.6

E249.7

E249.8

E249.9

E249.10

Example 14

E250E HCl was prepared using the procedures described above.

Using procedures analogous to those set forth for Schemes 15 and 16 andsubstituting appropriate starting materials, Examples E252-E254 (seeTable 14) could be synthesized.

TABLE 14

Example R—Z— X₁ X₂ X₃ E252  

3-Cl 5-F 3-F E253  

4-Cl H 3-F E253.1

H H H E253.2

4-Me 5-F 2-F E254  

H 4-Cl 3-F E254.1

4-Me 5-F 2-F E254.2

4-Cl H 3-F E254.3

H 5-F 3-F E254.4

4-Me H H E254.5

H H H

Example 15

A solution of rel-trans-2-phenylcyclopropane-1-carboxylic acid (2.0 g,12.33 mmol) in acetic acid (40 mL) was heated to 110° C. and treatedwith iodine (1.72 g, 6.78 mmol), KIO₃ (580 mg, 2.71 mmol) and 10% H₂SO₄(11 mL) and stirred at this temperature for 1 hour. TLC(Hexane-EtOAc-HOAc, 80:20:1) showed some starting material and mostlythe product. The reaction mixture was treated with iodine (200 mg),stirred 30 minutes at 110° C., cooled to the room temperature, treatedwith the mixture of saturated solutions of KHSO₄/Na₂S₂O₃ (50 mL/50 mL),extracted with EtOAc (300 mL, 2×100 mL), the organic layers were washedwith brine (50 mL), dried over Na₂SO₄ and concentrated. The crudeproduct (4.5 g) was purified using column chromatography on silica gel(Hexanes-EtOAc-HOAc, 99:1:0.1-90:10:0.1).rel-(1R,2R)-2-(4-iodophenyl)cyclopropane-1-carboxylic acid (3.2 g) wasisolated as a tan colored crystalline material. ES-API calc'd forC₁₀H₉IO₂ 287.96, [M−H]⁺ found 286.9

rel-(1R,2R)-2-(4-iodophenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E251) was prepared the same way as other amides (e.g., E247), ES-APIcalc'd for C₁₉H₁₅IN₂O 414.02, [M+H]⁺ found 415.0

Example 16

Preparation of tert-butyl2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylate (E255).

To trans-tert-butyl 2-((hydroxymethyl)phenyl)cyclopropane-1-carboxylatein DMF cooled to −40° was added NaH and the solution was stirred at −35°C.-−45° C. The reaction was warmed to −20° C. and benzyl bromide wasadded and the solution was warmed to 0° C. then to room temperature.After 2.5 hours the solution was poured into EtOAc and HCl (1 N) andfurther extracted with EtOAc, dried (Na₂SO₄) filtered and evaporated.Column chromatography 0-10% EtOAc-Hexanes have pure trans tert-butyl2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylate (E255).

Preparation oftrans-2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylic acid(E256)

To trans tert-butyl2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylate (E255) inCH₂Cl₂ was added trifluoroacetic acid and the solution was stirred atroom temperature for 7 hours. The solvents were evaporated to givetrans-2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylic acid(E256).

Preparation of2-(4-((benzyloxy)methyl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1-carboxamide(E257)

To trans-2-(4-((benzyloxy)methyl)phenyl)cyclopropane-1-carboxylic acid(E256) in pyridine was added EDC, DMAP and 6-aminoisoquinoline and thesolution was stirred at room temperature under N₂ overnight. The mixturewas poured into NaHCO₃ (sat) and EtOAc and further extracted with EtOAc,dried (Na₂SO₄), filtered and evaporated. Colum chromatography 4%MeOH—CH₂Cl₂ gave pure2-(4-((benzyloxy)methyl)phenyl)-N-(isoquinolin-611)cyclopropane-1-carboxamide(E257).

Preparation of N-(isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide(E259)

To 6-aminoisoquinoline in DMF cooled to 0° C. was added NaH and thesolution was stirred for 30 minutes. Then,2-phenylcyclopropane-1-carbonyl chloride was added and the solution wasstirred at 0° C. and warmed to room temperature for 3 hours. Thesolution was poured into EtOAc and NaHCO₃ (sat) and extracted withNaHCO₃ (sat). The organics were dried (Na₂SO₄), filtered and evaporated.Column chromatography 50-70% EtOAc-Hexanes gave pureN-(isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide (E259).

To 2-phenylcyclopropane-1-carboxylic acid in DMF was added EDC, DMAP and6-aminoisoquinoline and the solution was stirred overnight at roomtemperature under N₂. The mixture was poured into water and EtOAc andextracted, dried (Na₂SO₄) filtered and evaporated. Column chromatography0-10% MeOH—CH₂Cl₂ gave pureN-(isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide (E261).

Preparation ofN-(2-(□1-oxidanyl)-214-isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide(E263)

To N-(isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide (E262) inCH₂Cl₂ was added mCPBA and the solution was stirred at room temperatureovernight. The mixture was poured into dilute NaHSO₃ and extracted withEtOAc. The organics were dried (Na₂SO₄), filtered and evaporated. Columnchromatography 0-10% MeOH—CH₂Cl₂ gave pureN-(2-(11-oxidanyl)-214-isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide(E263).

Preparation of 6-(2-phenylcyclopropane-1-carboxamido)isoquinolin-1-ylacetate (E264).N-(2-(I1-oxidanyl)-2□4-isoquinolin-6-yl)-2-phenylcyclopropane-1-carboxamide(E263) was dissolved acetic anhydride and heated to reflux for 3.5 h.The acetic anhydride was evaporated and the mixture was taken up inCH₂Cl₂ and washed with NaHCO₃ (sat) and NaCl (sat), dried (Na₂SO₄),filtered and evaporated. Column chromatography 0-10% MeOH—CH₂Cl₂ gave6-(2-phenylcyclopropane-1-carboxamido)isoquinolin-1-yl acetate (E264)

Example 17: ROCK and JAK Assays

ROCK Kinase Inhibition Assays.

All compounds were initially prepared as 10 mM stocks in anhydrousdimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions wastransferred to individual wells in column 1 of a 96-well polypropylenemicrotiter plate (Corning #3363) and diluted with DMSO to give a finalcompound concentration of 4 mM. Test compounds were then seriallydiluted 1:5 in DMSO for an 11-point concentration response and furtherdiluted in the assay buffer bringing all compound concentrations to afinal range of 100 μM to 10 pM in 2.5% DMSO. The assay was performed inwhite 96-well, flat-bottom, half-area, non-binding assay plate (Corning#3642) in assay buffer consisting of 20 mM HEPES (pH 7.5), 10 mMMgCl₂*6H₂O, 100 μM sodium orthovanadate, 0.05% CHAPS and 0.1% bovineserum albumin. A 10 μL aliquot of compound from each well of theintermediate dilution plate and 20 μL of a 2× substrate/enzyme solutioncontaining acceptor substrate (800 nM RSK2 peptide KRRRLSSLRA (SEQ IDNO: 1)), ROCK2 enzyme (10 nM), or ROCK1 enzyme, and 1,4-Dithiothreitol(DTT, 2 uM) were added to all wells. The reaction was initiated by theaddition of 10 μL of 4× stock solution ATP (2 μM). Reactions werethoroughly mixed manually, covered and allowed to incubate at roomtemperature for 75 min. Protein kinase activity was quantitated usingPromega's KINASE-GLO™ luminescent Kinase Assay Kit according to themanufacturer's directions. ATP concentrations remaining in Test wellsfollowing the termination of the enzymatic reaction were comparedagainst control wells containing equivalent amounts of DMSO containingno inhibitor (CTRL). ATP concentrations in both Test wells and CTRLwells were normalized against background (BKG) ATP concentrations inwells containing concentrations of inhibitor that completely inhibitedthe protein kinase under investigation (i.e. a concentration thatprevented any consumption of ATP over the course of the incubation).Percent of Control (POC) values were determined for each concentrationof compound tested according to the equation:POC=((Test well value−BKG)/(CTRL−BKG))*100

IC₅₀ values were calculated using the following 4-parameter logisticcurve-fitting algorithm:f(x)=(A+((B−A)/(1+((x/C){circumflex over ( )}D))))

IC₅₀ values were converted to K values using the Cheng-Prusoff Equation:K_(i)=IC₅₀/(1+([ATP]/Km ATP])).

JAK Kinase Assays.

Compounds were prepared in the exact same manner as described in theROCK Kinase Assay with the exception to the substrate and enzyme. TheJAK 2× substrate/enzyme solution consisted of acceptor substrate (800 nMAbI peptide EAIYAAPFAKKK (SEQ ID NO: 2)), JAK2 or JAK3 enzyme (10 nM)and DTT (2 μM). All other steps and solutions remain identical to theROCK Kinase Assay above.

Results are shown below in Table 15, Table 16, and Table 17.

TABLE 15 Example Rho Kinase Activity No. Molecular Structure (JAK 2/3activity) E39.1

 75-110 nM E9

  3-5 nM (JAK2 65-100 nM) E12

  1-4 nM (JAK2 400 nM) E11/E13

  1-5 nM (JAK2 40-65 nM) E10

  1-7 nM

  5-13 nM E55

12,000-52,000 nM    (JAK2— inactive) E54

  1-2 nM (JAK2 15-90 nM) E8

  1-10 nM (JAK2 200 nM) E11/E13

  1.5-14 nM E14

  3.0-43 nM E30.1

 10-37 nM E15

  1-5 nM E17

  2-4 nM E30.2

  1-8 nM E56

 0.5-3.0 nM (40-120 nM JAK2) E96

 20-130 nM (1600-5000 nM JAK2) E99

 0.5-6.0 nM (250-600 nM JAK2) E18

 0.8-8.0 nM (1000-1200 nM JAK2) E115

 40-75 nM (3000-5000 nM JAK2) E116

100-400 nM (400-700 nM JAK2) E29.1

 0.5-1.0 nM (1000-6000 nM JAK2) 19.1

 30-60 nM (1500-3500 nM JAK2) E20.1

 0.5-2.0 nM (700-2000 nM JAK2) E16

 5.0-75 nM (2500-9000 nM JAK2) E251

150-400 nM (500-800 nM JAK2) E247A

 70-350 nM (5.0-25 nM JAK2) E247B

 8.0-35 nM (450-1450 nM JAK2) E142

 30-800 nM E143

190-250 nM (JAK2, 1300-2700 nM) E248D

 5.0-9.0 nM (JAK2 70-115 nM) E248E

 2.0-4.5 nM (JAK2 55-85 nM) E248H

 30-50 nM (JAK2 500-650 nM) E100.1

   25 nM (JAK2 inactive) E104.1

 15-75 nM (JAK2, inactive)

350-600 nM E19.2

  6.0-12 nM (JAK2, 300-350 nM) E20.2

 4.0-6.0 nM (JAK2, 27-150 nM) E32

 2.5-4.5 nM (JAK2 400-1300 nM) E31

 5.0-7.0 nM (JAK2, 375-570 nM) E248F

 3.0-5.0 nM (JAK2, 45-95 nM) E248G

 5.0-9.5 nM (JAK2, 50-65 nM) E250E*

  9.0-11 nM (JAK2, 13-17 nM) E33

 5.0-8.0 nM (JAK2, 75-110 nM) E34

  7.0-14 nM (JAK2, 30-45 nM) E35

 0.5-8.0 nM (JAK2, 300-950 nM) E191.1

105-155 nM (JAK2, 5200 nM) E37

 4.3-9.0 nM (JAK2, 800 nM) E38

 7.0-9.5 nM (JAK2 136 nM) E191

125-185 nM (JAK2 3000 nM) E158

165-215 nM (JAK2 1000 nM) E39

 5.0-7.0 nM (JAK2 400 nM) E193

 6.0-8.0 nM (JAK2 110 nM) E194

 3.5-4.0 nM (JAK2 15 nM) E195.1

 4.0-7.0 nM E195

 70-100 nM E160

250-800 nM E162.1

200-600 nM E36

 75-200 nM E15.1

 65-110 nM E162.2

125-300 nM E170

650-1250 nM  E159

 20-50 nM (JAK2 270 nM) E195.2

0.40-1.0 nM E57.1

0.15-1.0 nM (JAK2 45-65 nM) E174

0.15-0.30 nM  E173

 0.7-1.0 nM (JAK2 200 nM) E57.2

<0.10-1.0 nM (JAK2 7.0 nM) E115.1

<0.10-1.0 nM  E210

 60-300 nM E56.1

<0.10-0.5 nM  (JAK2 40-75 nM) Pyrrolidones

650-1350 nM  E223

8000-15000 nM   E224

2600-6750 nM  E230

14000-25000 nM   E227.1

1300-4000 nM  E225

1350-2200 nM  E227.2

300-600 nM E230.1

  9300 nM E231

34000-68000 nM   E226

1900-9300 nM  E232

6500-16000 nM   E233

4350-8400 nM  (JAK2 5800-13500 nM; JAK3 3400-3800 nM) E234.2

1000-1250 nM 

Compounds of Table 16, Table 17 and Table 18 can be prepared asdescribed in the typical procedures provided herein.

TABLE 16 Example Amount Rho Kinase Activity No. Structure (JAK 2/3activity) E265

75 154 17 36   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E266

6 9 2.0 12 9   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 nM IKKb E267

2.5 3.4 1.0 5.8 4.5   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 nM IKKb E268

24 85 12 125 650   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 nM IKKb

E269

9 25   nM ROCK2 nM ROCK1 E270

E271

8 9 116   nM ROCK2 nM ROCK1 nM JAK2 E272

5 5 87   nM ROCK2 nM ROCK1 nM JAK2 E273

4.0 4.0 70 1140   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E274

10 10 15 160   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E275

7.0 8.2 60   nM ROCK2 nM ROCK1 nM JAK2 E276

31 48 652   nM ROCK2 nM ROCK1 nM JAK2 E277

175 270 650   nM ROCK2 nM ROCK1 nM JAK2 E278

10 10 15 160   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E279

7.5 11 1150 2500   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E280

12.5 15 1400 1060   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E281

240 150 3000 7500   nM ROCK2 nM ROCK1 nM JAK2 nM JAK3 E282

E283

E284

E285

E286

E287

E288

E289

E290

E291

E292

E293

E294

TABLE 17

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (N-phenylsulfamoyl)phenyl)cyclopropane-1-carboxamide 75 nM ROCK2; 154 nM ROCK1 17 nM JAK2;36 nM JAK3 racemic

6 nM ROCK2; 9 nM ROCK1 2.0 nM JAK2; 12 nM JAK3 9 nM IKKb racemic

(1R,2R)-N-(isoquinolin-6-yl)-2-(4-(N- (pyridin-2-yl)sulfamoyl)phenyl)cyclopropane-1-carboxamide 1.0 nM ROCK2; 3.0 nM ROCK1 0.6 nM JAK2; 4.3nM JAK3 3.6 nM IKKb PTM: 61 nM

24 nM ROCK2; 85 nM ROCK1 12 nM JAK2; 125 nM JAK3 650 nM IKKb 7-foldselective JAK2/ROCK1 3.5-fold selective Rock2/1

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (N-(pyridin-3-ylmethyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide 9 nM ROCK2; 25 nMROCK1

(rel)-(1R,2R)-2-(4-(N-(3-(dimethylamino) propyl)sulfamoyl)phenyl)-N-(isoquinolin-6-yl)cyclopropane-1- carboxamide

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (N-(piperidin-4-ylmethyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride 8nM ROCK2; 9 nM ROCK1 JAK2 116 nM

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (N-(((S)-piperidin-3-yl)methyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride 5nM ROCK2; 5 nM ROCK1 JAK2 87 nM

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (N-(((R)-piperidin-3-yl)methyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride4.0 nM ROCK2; 4.0 nM ROCK1 JAK2- 70 nM; JAK3- 1140 nM

10 nM ROCK2; 10 nM ROCK1 15 nM JAK2 160 nM JAK3

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4-(N-(piperidin-4-yl)sulfamoyl)phenyl) cyclopropane-1-carboxamidedihydrochloride 7.0 nM ROCK2; 8.2 nM ROCK1 JAK2 60 nM

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4- (piperazin-1-ylsulfonyl)phenyl)cyclopropane-1-carboxamide dihydrochloride 31 nM ROCK2; 48 nM ROCK1 JAK2652 nM

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(4-(methylpiperazin-1-ylsulfonyl)phenyl) cyclopropane-1-carboxamidedihydrochloride

(rel)-(1R,2R)-2-(4-iodophenyl)-N- (isoquinolin-6-yl)cyclopropane-1-carboxamide 175 nM ROCK2; 270 nM ROCK1 JAK2 650 nM

(rel)-(1R,2R)-N-(4-chloroisoquinolin-6- yl)-2-(4-(N-(((R)-piperidin-3-yl)methyl)sulfamoyl)phenyl)cyclopropane- 1-carboxamide dihydrochloride10 nM ROCK2; 10 nM ROCK1 15 nM JAK2 160 nM JAK3

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2-(3- (N-phenylsulfamoyl)phenyl)cyclopropane-1-carboxamide 7.5 nM ROCK2; 11 nM ROCK1 1150 nMJAK2; 2500 nM JAK3

12.5 nM ROCK2; 15 nM ROCK1 1400 nM JAK2; 1060 nM JAK3

240 nM ROCK2; 150 nM ROCK1 3000 nM JAK2; 7500 nM JAK3

rel-N-(4-chloroisoquinolin-6-yl)-2-(4- (N-(pyridin-2-yl)sulfamoyl)phenyl)cyclopropane-1-carboxamide racemic 8.0 nM ROCK2; 13 nM ROCK1 0.55nM JAK2; 0.70 nM JAK3 9.0 nM IKKb PTM: 227 nM (PKA = 285 nM, PromiscuityIndex = 475)

N-(4-chloroisoquinolin-6-yl)-2-(4-(N- (pyridin-2-yl)sulfamoyl)phenyl)cyclopropane-1-carboxamide chiral, nonracemic

rel-N-(4-methylisoquinolin-6-yl)-2-(4-(N-(pyridin-2-yl)sulfamoyl)phenyl) cyclopropane-1-carboxamide racemic

(1R,2R)-N-(isoquinolin-6-yl)-2-(4-(N- (pyridin-2-yl)sulfamoyl) 3-fluorophenyl) cyclopropane-1-carboxamide

N-(5-fluoroisoquinolin-6-yl)-2-(4-(N- (pyridin-2-yl)sulfamoyl)phenyl)cyclopropane-1-carboxamide racemic 4.9 nM ROCK2; 10.3 nM ROCK1 20nM JAK2; 130 nM JAK3 144 nM IKKb PTM: 290 nM

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2- (4-(methylpiperazin-1-ylsulfonyl)phenyl) cyclopropane-1-carboxamide dihydrochloride

rel-N-(4-methylisoquinolin-6-yl)-2-(4-(N-(pyrimidin-2-yl)sulfamoyl)phenyl) cyclopropane-1-carboxamide racemic

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2- (4-(N-(piperidin-3-yl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2- (4-(N-(((R)-piperidin-3-yl)methyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride

(rel)-(1R,2R)-N-(isoquinolin-6-yl)-2- (4-(N-(((S)-piperidin-3-yl)methyl)sulfamoyl)phenyl) cyclopropane-1-carboxamide dihydrochloride

TABLE 18

Example 18. PTM-HTM Assay

Porcine Trabecular Meshwork cells (PTM) were isolated from freshlyobtained enucleated porcine eyes. Immortalized Human Trabecular Meshworkcells (TM-1) were obtained through a kind gift from Donna Peters in theDepartment of Ophthalmology and Visual Sciences at the University ofWisconsin. Cells were plated onto fibronectin coated glass-bottom96-well plates and allowed to attach overnight. Media was removed andreplaced with test compound in media with 1% fetal bovine serum andincubated for various times. After incubation, cells were formaldehydefixed, triton solubilized, and stained. PTM cells were stained withAlexa Fluor®488 phalloidin (F-actin) and Hoechst 33342 (nuclei). TM-1cells were stained with anti-paxillin followed by Alexa Fluor®488goat-anti-mouse IgG (focal adhesions) and Hoechst 33342 (nuclei). Allstaining reagents were obtained through Invitrogen. Images werecollected on an INCell 2200 imager with a 20× objective. The actin fiberlength and total area of focal adhesions were analyzed using customalgorithms developed in the INCell Developer Toolbox, v1.9.3. Datacollected were converted to percent of control (untreated cells). Curveswere fit to data in GraphPad Prizm using sigmoidal dose-response andconstraining top and bottom to 100% and 0%, respectively.

Example 19

Topical pharmaceutical compositions for lowering intraocular pressureare prepared by conventional methods and formulated as follows:

Ingredient Amount (wt %) Arylcyclopropyl amino acid isoquinolyl 0.50amide Dextran 70 0.1 Hydroxypropyl methylcellulose 0.3 Sodium Chloride0.77 Potassium chloride 0.12 Disodium EDTA 0.05 Benzalkonium chloride0.01 HCl and/or NaOH pH 4.5-6.5 Purified water q.s. to 100%

A compound according to this disclosure is used as the arylcyclopropylamino acid isoquinolyl amide. When the composition is topicallyadministered to the eyes once daily, the above composition decreasesintraocular pressure in a subject suffering from glaucoma.

Example 20

Reference Example One. Pharmacological Activity for Glaucoma Assay.

Pharmacological activity for glaucoma can also be demonstrated usingassays designed to test the ability of the subject compounds to decreaseintraocular pressure. Examples of such assays are described in thefollowing reference, incorporated herein by reference: C. Liljebris, G.Selen, B. Resul, J. Sternschantz, and U. Hacksell, “Derivatives of17-phenyl-18, 19, 20-trinorprostaglandin F_(2α) Isopropyl Ester:Potential Anti-glaucoma Agents”, Journal of Medicinal Chemistry 1995, 38(2): 289-304.

FIG. 1 shows changes (reductions) in rabbit IOP achieved withintracameral injection of a formulation of a(1R,2R)—N-(fluoroisoquinolin-6-yl)-2-(4-(pyridinylmethyl)phenyl)cyclopropane-1-carboxamide.

While the disclosure has been described in detail and with reference tospecific embodiments thereof, it will be apparent to one skilled in theart that various changes and modifications can be made without departingfrom the spirit and scope of the disclosure.

What is claimed is:
 1. A compound of Formula (X):

or a pharmaceutically acceptable salt thereof, wherein, R¹ is H, —C₁₋₆alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆ alkyl)-pyridinyl,—(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl;R² is H, —C₁₋₆ alkyl, —C₁₋₆ haloalkyl, aryl, heteroaryl, —(C₁₋₆alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴, —(C₁₋₆ alkyl)-heterocyclyl orheterocycloalkyl; or R¹ and R², together with the nitrogen to which theyare attached, form a heterocyclyl; R³ is H, C₁₋₆ alkyl or —C₁₋₆haloalkyl; R⁴ is H, C₁₋₆ alkyl or —C₁₋₆ haloalkyl; X is H, C₁₋₆ alkyl,—C₁₋₆ haloalkyl, halogen or hydroxyl; Y is H, C₁₋₆ alkyl, —C₁₋₆haloalkyl, halogen or hydroxyl; and Z is H, C₁₋₆ alkyl, —C₁₋₆ haloalkyl,halogen or hydroxyl.
 2. The compound of claim 1, wherein the compound ofFormula (X) is: a compound of Formula (XI):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XII):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XIII):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XIV):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XV):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XVI):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XVII):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XVIII):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XIX):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XX):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XXI):

or a pharmaceutically acceptable salt thereof; a compound of Formula(XXII):

or a pharmaceutically acceptable salt thereof; or a compound of Formula(XXIII):

or a pharmaceutically acceptable salt thereof.
 3. The compound of claim1, wherein R¹ is H or —C₁₋₆ alkyl.
 4. The compound of claim 1, whereinR² is phenyl, pyridinyl, —(C₁₋₆ alkyl)-pyridinyl, —(C₁₋₆ alkyl)-N(R³)R⁴,—(C₁₋₆ alkyl)-heterocyclyl or heterocycloalkyl.
 5. The compound of claim1, wherein R² is 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl.
 6. Thecompound of claim 1, wherein R¹ and R², together with the nitrogen towhich they are attached, form a heterocyclyl containing six ring atoms.7. The compound of claim 1, wherein R¹ and R², together with thenitrogen to which they are attached, form a heterocyclyl containing sixring atoms, wherein one or two of the ring atoms are, independently, O,S or N.
 8. The compound of claim 1, wherein R¹ and R², together with thenitrogen to which they are attached, form a heterocyclyl containing sixring atoms, wherein one or two of the ring atoms are N.
 9. The compoundof claim 1, wherein R³ and R⁴ are H, or R³ and R⁴ are, independently,C₁₋₆ alkyl.
 10. The compound of claim 1, wherein: X is C₁₋₆ alkyl,halogen or hydroxyl; and Y and Z are H.
 11. The compound of claim 1,wherein X is C₁₋₆ alkyl, halogen or hydroxyl.
 12. The compound of claim1, wherein X, Y, and Z are each, independently, methyl, ethyl, CF₃, CHF₂or CH₂F.
 13. The compound of claim 1, wherein X is halogen.
 14. Thecompound of claim 1, wherein Z is H or F.
 15. A compound, selected from:

or a pharmaceutically acceptable salt thereof.
 16. A composition,comprising the compound of claim
 1. 17. A pharmaceutical composition,comprising the composition of claim 16 and a pharmaceutically acceptablecarrier.
 18. A method of treating an ocular disorder in a subject inneed thereof, comprising administering to the subject the compound ofclaim
 1. 19. The method of claim 18, wherein the ocular disorder isglaucoma, an inflammatory eye disease, a neurodegenerative eye disease,diabetic eye disease, wet age-related macular degeneration, or dryage-related macular degeneration.
 20. A method of reducing intraocularpressure in a subject in need thereof, comprising administering to thesubject the compound of claim
 1. 21. A method of modulating kinaseactivity in a cell, comprising contacting the cell with a compound ofclaim
 1. 22. The compound of claim 1, wherein the compound is:

or a pharmaceutically acceptable salt thereof.
 23. A composition,comprising the compound of claim
 15. 24. A pharmaceutical composition,comprising the composition of claim 23 and a pharmaceutically acceptablecarrier.
 25. A method of treating an ocular disorder in a subject inneed thereof, comprising administering to the subject the compound ofclaim
 15. 26. The method of claim 25, wherein the ocular disorder isglaucoma, an inflammatory eye disease, a neurodegenerative eye disease,diabetic eye disease, wet age-related macular degeneration, or dryage-related macular degeneration.
 27. A method of reducing intraocularpressure in a subject in need thereof, comprising administering to thesubject the compound of claim
 15. 28. A method of modulating kinaseactivity in a cell, comprising contacting the cell with a compound ofclaim 15.